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RÉSUMÉ 
Le but de cette étude était d’évaluer les qualifications de performance du 
système FlexiWare® chez le rat male Sprague Dawley et le singe Cynomolgus 
éveillés, ainsi que chez le chien Beagle éveillé et anesthésié, suite à 
l’administration de produits ayant une activité pharmacologique connue. Les 
produits utilisés incluaient l’albutérol administré par inhalation, la méthacholine, 
et le rémifentanil administrés par voie intraveineuse. Une solution saline 
administré par voie intraveneuse, a été utilisée comme substance témoin. 
Différentes variables ont servi à évaluer la réponse des animaux (rats, chien, 
singe). Ces dernières comprenaient la fréquence respiratoire (RR), le volume 
courant (TV), la ventilation minute (MV). Des paramètres additionnels ont été 
évalués chez le rat, soit les temps d’inspiration (IT) et d’expiration (ET), le 
temps du pic de débit expiratoire, les pics de débits inspiratoire et expiratoire, le 
ratio  inspiratoire:expiratoire (I:E), le ratio inspiratoire sur respiration totale 
(I:TB), et l’écoulement expiratoire moyen (EF50). 
Les résultats obtenus ont démontré que le système FlexiWare® était 
suffisamment sensible et spécifique pour dépister, chez les espèces animales 
utilisées, les effets bronchodilateur, bronchoconstricteur et dépresseur central des 
substances testées. Il pourrait  faire partie des méthodes (ICH 2000) utilisées en 
pharmacologie de sécurité lors de l’évaluation de substances pharmacologiques 
sur le système respiratoire des animaux de laboratoire. Les espèces animales 
utilisées ont semblé s’adapter aisément aux procédures de contention. Les 
paramètres évalués, RR, TV et MV ont permis de caractériser la réponse des 
animaux suite à l’administration de produits pharmacologiques à effets connus, 
judicieusement complétés par les variables de débit. L’ajout de paramètres du 
temps n’était pas primordiale pour détecter les effets des drogues, mais offre des 
outils complémentaires d’interpréter les changements physiologiques. 
Cependant, chez le rat conscient, la période d’évaluation ne devrait pas s’étendre 
au-delà d’une période de deux heures post traitement. 
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Ces études constituent une évaluation des qualifications de performance 
de cet appareil et ont démontré de manière originale, la validation 
concurrentielle, en terme de précision (sensibilité et spécificité) et fiabilité pour 
différentes variables et sur différentes espèces. 
MOTS CLÉS :  
Respiration, Sécurité, Pharmacologie, Rats, Chiens, Singes, Validation. 
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ABSTRACT 
The aim of this study was to evaluate the performance qualifications of 
the FlexiWare® system in conscious Sprague-Dawley rats, Cynomolgus 
monkeys, as well as awake and anesthetized Beagle dogs following the 
administration of pharmacological substances with known effects on the 
respiratory system. The pharmacological substances included albuterol 
administered by inhalation; methacholine and remifentanil, both administered 
intravenously. A preparation of saline solution administered intravenously was 
used as control. Respiratory monitoring included: respiratory rate (RR), tidal 
volume (TV), minute ventilation (MV), in rats, dogs and monkeys. Additional 
time-, flow-, and ratio-derived variables were used in the rat model. Those 
variables included inspiratory (IT) and expiratory (ET) times, time to peak 
expiratory flow, peak inspiratory and expiratory flows, mid-tidal expiratory flow 
(EF50), inspiratory:expiratory (I:E) and inspiratory to total breath (I:TB) ratios.  
The results of this study have proven that the FlexiWare® was a reliable 
method and should be considered in the core battery recommended in safety 
pharmacology studies (ICH 2000) to assess the broncho-dilative, -constrictive, 
and central depressant effects of drugs on the respiratory system of the common 
laboratory animal species. The animals appeared to adapt well to the restraint 
unit. The variables evaluated, particularly RR, TV and MV, were adequate and 
allowed to characterize the response of the animals following the administration 
of the pharmacological substances. They are judiciously completed with flow-
derived variables. The addition of within-breath time parameters was not 
primordial to detect drug effects but offered complementary tools to interpret 
physiological changes. However the evaluation period should be limited to the 
first 2 hours post treatment. 
These studies represent a performance qualifications evaluation of the 
system and have originally demonstrated the precision (sensitivity and 
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specificity) as well as repeatability for different variables and on different 
species of interest. 
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INTRODUCTION 
In the drug development process, the testing of new drugs in laboratory 
animals is a prerequisite (Jasso 2002). The objective of this evaluation is to 
quantify the effects of potentially new drugs on different animal physiological 
functions in order to assess their safety. It is recommended to test on two 
different animal species, one rodent species, normally the rat, and one non-
rodent species, either the dog or a non-human primate (Wallas 2001).  
The International Conference of Harmonization (ICH) (2000) was 
responsible to define the guidelines used in safety pharmacology studies. Those 
studies are part of pharmacology studies, which are divided into three categories: 
primary pharmacodynamic, secondary pharmacodynamic and safety 
pharmacology studies (FDA 1997). The term “Safety Pharmacology” was first 
defined at the ICH in 2001 (ICH 2001). The aim of this discipline is to 
characterize the pharmacokinetic / pharmacodynamic relationship (PK / PD) of 
drug’s effects using continuously evolving methodology (Pugsley et al. 2008).  
Pharmacology studies have been considered an important component in drug 
safety assessment. The reason is that numerous examples are reported in the 
literature indicating that conventional preclinical toxicity testing methods could 
not predict problems occurring following the administration of new dugs to 
patients. Some of the problems are hepatotoxicity (Peters 2005) and central 
nervous system effects (Tsaioun et al. 2009). 
The safety pharmacology studies are defined as those that investigate the 
potential undesirable pharmacodynamic effects of a substance on physiological 
functions, in relation to exposure in the therapeutic range. The respiratory system 
is an essential part of the core battery recommended in safety pharmacology 
studies (ICH 2000). The effects of the test substance on the respiratory system 
should be assessed appropriately. Clinical observations of animals are generally 
not adequate to assess respiratory function. Respiratory rate (RR) and other 
measures of respiratory function such as airway resistance, compliance, 
pulmonary arterial blood pressure, blood gases, and pH are recommended. Those 
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parameters should be quantified by using appropriate methodologies (ICH 
2000). 
This literature review will include the anatomy and physiology of the 
respiratory system of the different species, rats, dogs and monkeys used in this 
study. The rules and use of safety pharmacology will also be included.  
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LITTERATURE REVIEW 
 
1. ANATOMY OF THE RESPIRATORY SYSTEM 
The anatomy of the respiratory tract differs among species. The shape of 
both the upper and lower respiratory tract; the extent, shape, and pattern of the 
turbinate bones; the branching patterns of bronchi; the anatomy of terminal 
bronchioles, including collateral ventilation; the lobation and lobulation of the 
lungs; the thickness of the pleura; the completeness of the mediastinum; 
relationship of pulmonary arteries to bronchial arteries and bronchioles; the 
presence of vascular shunts and the blood supply could be different from one 
species to the other. Each variation in the anatomic structure could imply 
possible variations in the respiratory function (Reznick 1990). 
However, some animal species have anatomically similar respiratory tracts. 
For instance, the dogs, monkeys and rats are similar while horses are closer to 
the human respiratory tract (Merck 2008). The respiratory system can be 
subdivided into the upper and the lower respiratory tracts based on anatomical 
features (Carter 2007).  
1.1. The upper respiratory tract 
The upper respiratory tract includes the nose, nasal passages, pharynx, 
larynx, and trachea (fig. 1), In addition to the obviously wide range of size and 
external shapes of the nose, there are also interspecies differences in the internal 
anatomy and physiology of the upper respiratory tract.  
The upper respiratory structures of the tract act to tunnel fresh air down, 
from outside to inside the body. The upper airways are important because they 
must always stay open to be able to breath. 
The nose assists in the production of sound and in olfaction. The most 
important function is to warm and to humidify the air through a highly 
vascularized mucus membrane covering the inside of the nose. The upper one-
third of the nasal cavity is lined with olfactory epithelium which sits on the 
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lamina propria containing numerous serous and mucus glands while the lower 
two-thirds are lined with pseudostratified ciliated columnar epithelium 
containing high amount of goblet cells. Goblet cells, with microvilli on the 
surface, are present through the respiratory tract. Those cells are responsible for 
mucus secretion. The microvilli retain particles in the pharynx where they are 
swallowed to prevent foreign bodies to penetrate the lungs (Rusell 2004). The rat 
has a smaller percentage of goblet cells than man. Also, secretory cells are more 
frequent in rats compared to humans, except in the terminal bronchioles where 
they are comparable (Miller et al. 1993). In the resting animal, the nasal cavity, 
pharynx and larynx, provide approximately 60% of the frictional resistance to 
breathing (Cunningham & Klein 2007). In animals, nasal resistance can be 
decreased by dilation of the external nares and by vasoconstriction which 
reduces the volume of blood in the vascular sinuses within the nasal mucosa and, 
as a consequence, the mucosal thickness decreases and the space available for air 
within the nose increases(Cunningham & Klein 2007). 
 The pharynx extends from the base of the skull to the inferior border of 
the cricoid cartilage. It is divided into 3 parts: nasopharynx, oropharynx and 
laryngopharynx. The oropharynx also has a digestive function. It is delimited by 
the soft palate superiorly, the basis of the tongue inferiorly, the palatoglossal and 
the palatopharyngeal arches on lateral sides. The laryngopharynx or 
hypopharynx also has a digestive function and lies caudally to the larynx, 
extending from the superior border of the epiglottis and the pharyngo-epiglottic 
folds to the inferior border of the cricoid cartilage, when it narrows and becomes 
in continuity through the esophagus (Moore et al. 2006). Both are lined with 
non-keratinized stratified squamous epithelium. The nasopharynx includes the 
respiratory area, which is adapted to its main functions of filtering, warming, and 
humidifying (McGowan et al. 2003). It lies superior to the soft palate and is the 
posterior extension of the nasal cavities (Moore et al. 2006). 
The larynx is located at the crossroads of the air and food passages. It 
includes the epiglottis, the thyroid, as well as the arytenoid and cricoid 
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cartilages. The larynx, by its position, prevents the accidental introduction of 
foreign bodies in the trachea. Its cranial end is attached to the hyoid bone and 
lies below the epiglottis, while its caudal end is in continuity with the trachea. 
One of the larynx main functions is to assist in warming and humidifying 
incoming air. The epiglottis is a structure, which serves to guide the larynx 
upwardly behind the soft palate so it can lock into the nasopharynx.  
In rats, the larynx began at the opening bounded anteriorly by the free 
border of the epiglottis. The length of the larynx is 4–5 mm. The cricoid 
cartilage formed a complete ring at the inferior aspect of the larynx and is fixed 
to the tracheal rings (Nayci 2004). The thyroid cartilage, is a wedge shaped 
structure of which sides are called laminae. The thyroid cartilage articulates with 
the cricoid cartilage at the inferior side, cornually and bilaterally. The arytenoid 
cartilages are bilaterally situated and shaped like small three side pyramids, the 
bases of which are concave, representing the articular facets that glide upon the 
corresponding facets of the posterosuperior aspect of the cricoid lamina (Harvey 
1993). The cricoid cartilage sits next to the thyroid; its function is to provide 
attachments for the various muscles, cartilages, and ligaments involved in 
opening and closing the airways and in vocalization production. The cricoid 
cartilage is roughly circular in shape inferiorly, and above, it follows the outline 
of the glottis. In other non-human mammals, cricothyroid joints vary in size and 
may be absent (Norris 1995). The principal role of airway smooth muscle is to 
control airway calibre, so the balance between resistance to airflow and 
physiological dead space is optimised (Matera et al 2002).  
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Figure 1. Schema of the upper respiratory tract of dogs (Printed from 
http://www.vetmed.wsu.edu/cliented/anatomy/dog_resp.aspx) 
 
1.2. The lower respiratory tract  
The lower respiratory tract includes the bronchi, the bronchioles, and the 
lungs. The lower respiratory tract structure varies both within a species and 
among specie. Irregular dichotomous and trichotomous airway branching 
patterns are present in human and nonhuman primate lungs. In contrast, the dog 
and common laboratory rodents exhibit a predominantly monopodial branching 
system (Miller et al 1993). In most laboratory rodents, the conducting airway 
terminates abruptly, therefore non-cartilaginous non-alveolarized airways, 
terminal brochioles open into a completely alveolarized airway (Bal & Ghoshal 
1988). The trachea is nearly but not quite cylindrical, being flattened on the 
posterior. The trachea helps to direct inspired air to the gas exchanging regions 
of the lung (West 2005).  
In dogs, the trachea extends from a transverse plane through the middle 
of the axis to a plane between the fourth and fifth thoracic vertebrae. It is 
composed of approximately 35 C-shaped tracheal cartilages. They are open 
dorsally and the space is bridged by the tracheal muscle (Evans et al 1988). At 
examination the trachea will be felt as a firm, tubular structure extending 
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throughout much of the cervical length on the vertical surface of the neck near 
the midline, the cartilaginous nature of the trachea allows it to be grasped 
between the fingers. Incomplete cartilaginous rings are bridged by the trachealis 
muscle (Smith 1999).   
In rats, the length and internal diameter of the trachea is 25–27 mm and 
3–4 mm, respectively. The cranial surface of the trachea is convex, and covered, 
in the neck area, in a cranio-caudal direction, by the isthmus of the thyroid gland, 
the inferior thyroid veins, the arteria thyroidea ima, the sternothyreoideus and 
sternohyoideus muscles, and the cervical fascia. Caudally, it is in contact with 
the esophagus. Laterally, in the neck, it is in relation with the common carotid 
arteries, the right and left lobes of the thyroid gland, the inferior thyroid arteries 
and, the recurrent nerves. In the thorax, it lies in the cranial mediastinum, and is 
in relation on the right side with the pleura and right vagus, and near the root of 
the neck, with the innominate artery. On its left side are the left recurrent nerve, 
the aortic arch, and the left common carotid and subclavian arteries (Gray 2000). 
The muscular tissue consists in two layers (longitudinal and transverse) of non-
striated muscle. The longitudinal fibers are external, and consist of a few 
scattered bundles. The transverse fibers are internal and form a thin layer, which 
extends transversely between the ends of the cartilages (Goldbloom et al. 1960).  
The mediastinum in primates and dogs are comparable (Miller et al. 1996). This 
structure can be divided into a cranial part, lying cranial to the heart; a middle 
part, containing the heart; and a caudal part, lying caudal to the heart. The caudal 
mediastinum is thin. It attaches to the diaphragm far to the left of the median 
plane. Cranially it is continous with the middle mediastinum (Evans 1988). 
In rodents, the potential space between the medial walls of the two 
visceral pleurae is called the mediastinum. It is nearly filled with structures 
including an endocrine gland called the thymus and the parietal pericardium 
(Wingerd 1988). The tracheobronchial tree is a branching system that delivers 
air to the alveoli. The number of branches depends on the animal’s size. For 
instance, mice have about 10 and horses 40 or more. The tracheobronchial tree is 
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lined by a secretory, ciliated epithelium. The bronchi are supported by cartilage 
and supplied with bronchial glands and goblet cells, the secretions of which 
contribute to the mucous lining of the airways. The smaller airways, known as 
bronchioles, lack cartilages, glands and goblet cells. With the exception of the 
trachea and the cranial part of the mainstream bronchi, the airways are 
intrapulmonary. Alveolar septa attach to the outer layers of the airways so that 
tension within the septa pulls the airways open and helps to maintain their 
patency (Cunningham & Klein 2007).  
The alveolar ducts and alveoli primarily consist of simple squamous 
epithelium that permits rapid diffusion of oxygen (O2) and carbon dioxide (CO2). 
Gas exchange between the air in the lungs and the blood in the capillaries occurs 
across the walls of the alveolar ducts and alveoli (Bray et al. 1999).  
The alveolar duct branching system of the rat is complex (Miller et al. 
1993). It is a three dimensions system in which multiple branches may occur 
within the distance of a single alveolus. The alveolar duct system of the rat is 
only about 100 µm.  
In primates, the bronchioles are arranged stereotaxically like those of 
other mammalian lungs. The four bronchiole systems, dorsal, ventral, medial, 
and lateral, arise from both bronchi, respectively, although some bronchioles are 
lacking. In the right lung, the bronchioles form the upper, middle, accessory, and 
lower lobes, while in the left lung, the upper and accessory lobes are lacking and 
bi-lobed middle and lower lobes are formed (Nakakuki 1986). 
The lungs are a pair of sponge-like organs located inside the thoracic 
cavity. They are not directly attached to the ribs. They are suspended by a 
double-walled sac called pleura (Wilmore et al. 2008). The inner layer of the sac 
(visceral pleura) tightly adheres to the lungs, and the outer layer (parietal pleura) 
is attached to the wall of the chest cavity. The two layers are separated by a thin 
space, called the pleural cavity, filled with pleural fluid allowing the inner and 
outer layers to slide over each other, and prevent them from being easily 
separated. The liquid allows the two pieces to slide over one another but makes 
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them difficult to separate. In the thorax, therefore, the pleural fluid mechanically 
links the lungs to the thorax so that the respiratory system behaves as a single 
unit. The lungs of most species have a total of six lobes, each supplied by a lobar 
bronchus, which gives rise to daughter bronchi. Even in specie such as the horse 
that lack lobation, the same pattern of six lobar bronchi is still present. At each 
division of a parent bronchus, the diameter of the other is similar to that of the 
parent (Cunningham & Klein 2007). 
The primarily function of the lungs is to allow O2 to move from the air 
into the venous blood and CO2 to move out (West 2005). The air enters through 
the trachea going to the left and right bronchi and branch many times throughout 
the lungs, until they eventually form a little thin walled air sacs or bubbles, 
known as the alveoli. The alveoli are the sites of gas exchange with the blood 
(Widmaier et al. 2006).  
The lungs present few differences between laboratory animal species. In 
dogs, each lung is roughly triangular and has apex, costal, medial, diaphragmatic 
surfaces, dorsal, ventral, and caudal borders. Each lung is divided by deep 
fissures into distinct lobes. The caudal fissures of the dog’s lungs correspond to 
the oblique fissures of the human lungs (Ishaq 1980). Dogs like humans, have 
right and left lungs. Both sides of the lungs are further divided into lobes. Inside 
the lungs, the bronchi divide into smaller and smaller tubes, called bronchioles, 
much like branches of a tree divide into smaller and smaller branches. 
 In primates, the lungs of the rhesus monkeys are generally separated into 
six lobes. The left lung has two lobes, cranial and caudal, of which the cranial is 
further segmented into a cranial and caudal portion. The right lung has four 
distinct lobes in the rhesus monkeys. The lungs are lined by connective tissue 
band with a mesothelial surface facing the pleural space (Wolfe-Coote 2005). 
In the rat, the lungs are large spongy structures. The right lung is divided 
into four lobes: cephalic, medial, caudal and postcaval (Fig. 2) (Wingerd 1988).   
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Figure 2.  Rat lungs anatomy (Printed from www.tutorvista.com) 
 
1.3. Pulmonary blood flow  
The lung receives blood flow from two circulatory systems: the 
pulmonary circulation and the bronchial circulation. The pulmonary circulation 
receives the total output of the right ventricle, perfuses the alveolar capillaries 
and participates in gas exchange. The bronchial circulation, a branch of the 
systemic circulation, provides a nutritional blood supply to airways and other 
structures within the lung (Cunningham & Klein 2007). 
The pulmonary circulation carries roughly the same flow as the systemic 
circulation. The arterial pressure and the vascular resistance are normally only 
one-sixth as great. The media of the pulmonary arteries is about half as thick as 
in systemic arteries of corresponding size. In the larger vessels, it mainly 
consists of elastic tissue but in the smaller vessels, it is mainly muscular. The 
transition in vessels is close to 1 mm diameter. Pulmonary arteries lie close to 
the corresponding air passages in connective tissue sheaths (Lumb 2006). The 
bronchial circulation provides nutrient blood flow to airways, large blood 
vessels, and the pleura (Mc Laughlin et al. 1961). 
The pulmonary circulation begins at the main pulmonary artery, which 
receives the mixed venous blood pumped by the right ventricle. The main 
pulmonary arteries that accompany the bronchi are elastic, but the smaller 
arteries adjacent to the bronchioles and the alveolar ducts are muscular 
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(Cunningham & Klein 2007). This, then branches successively like the system of 
airways and, indeed, the pulmonary arteries accompany the airways as far as the 
terminal bronchioles. Beyond that, they break up to supply the capillary bed 
which lays in the alveoli walls. The pulmonary capillaries form a dense network 
in the alveolar wall which makes an exceedingly efficient arrangement for gas 
exchange (Fig. 3). The oxygenated blood is then collected from the capillary bed 
by the small pulmonary veins that run between the lobules which drain into the 
left atrium (West 2005). 
 
Figure 3.  Surface view of capillaries in alveolar wall(Printed from: Guyton, 
A.C. & Hall, J.E., 2006. Textbook of Medical Physiology., p 497) 
 
The amount of smooth muscle in the media of pulmonary arteries determines the 
reactivity of the vasculature. The small pulmonary arteries lead into pulmonary 
capillaries, which form an extensive branching network of vessels within the 
alveolar septum,  covering almost the alveolar surface. Not all capillaries are 
perfused in the resting animal. As a result, vessels that are unperfused can be 
recruited when pulmonary blood flow increases. Pulmonary veins with thin walls 
conduct blood from capillaries to the left atrium and also form a reservoir of 
blood for the left ventricle (Fig 4) (Cunningham & Klein 2007). 
In the bronchioles, oxygenated arterial blood flows to the lungs through 
small bronchial arteries that originate from the systemic circulation. After this 
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bronchial and arterial blood has passed through the supporting tissues, it empties 
into the pulmonary veins and enters the left atrium. Therefore, the flow into the 
left atrium and the left ventricular output are about 1 to 2 per cent greater than 
the right ventricular output (Guyton et al. 2006). 
 
 
Figure 4. Pulmonary blood circulation (Printed from www.mhhe.com)  
 
1.4. Muscles of respiration  
 
Energy provided by muscles causes air to enter the lungs during 
inhalation. During exhalation, much of the energy causing air to leave the lungs 
is provided by the elastic energy stored in the stretched lung and the thorax 
(Cunningham and Klein 2007). There are several muscles which play an 
important role in the inspiration and expiration process during breathing (Adams 
1998).  
The inspiration muscles are composed of the diaphragm, the external 
intercostal muscles, and the accessory muscles. The accessory muscles include 
the scalene muscles and the sternomastoids. Other muscles playing a minor role 
include the alae nasi, which causes flaring of the nostrils and, small muscles in 
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the neck and head. The primary inspiration muscle is the diaphragm, which is a 
domed musculotendinous sheet separating the abdomen and thorax and 
innervated by the phrenic nerve, responsible for an active inhalation. The 
external intercostals muscles also are active during inhalation. The fibers of 
these muscle contraction moves the ribs rostrally and outward. The relative 
contributions of diaphragmatic and costal movements to ventilation under 
different metabolic demands are not well defined in animals. Because the cranial 
ribs support the forelimbs in quadrupeds, they participate less in ventilation than 
do the more caudal ribs. Other inspiratory muscles include those connecting the 
sternum and head. These muscles contract during stenous breathing and move 
the sternum rostrally (Cunningham & Klein 2007). 
During expiration, the most important muscles are those of the abdominal 
wall, including the rectus abdominis, internal and external oblique muscles and 
transversus abdominis. The internal intercostal muscles also assist during the 
process (West 2005). Contraction of the abdominal muscles increases abdominal 
pressure, which forces the relaxed diaphragm forward and reduces the size of the 
thorax. The fibers of the internal intercostals are directed cranio-ventrally, from 
the cranial border of one rib to the caudal border of the next cranial rib, so their 
contraction decreases the size of the thorax by moving the ribs caudally and 
ventrally. As the thorax becomes smaller, the thoracic pressure increases and 
forces air out of the lungs (Cunningham & Klein 2007). 
 
2. PHYSIOLOGY OF THE RESPIRATORY SYSTEM 
In mammals, the function of the respiratory system is essential to 
maintain homeostasis (National Research Council 2003). Its major function is 
gas exchange between the external environment and the organism's circulatory 
system. This exchange facilitates oxygenation of the blood with concomitant 
removal of CO2 and other gaseous metabolic wastes from the circulation as 
water, sulfates, phosphates and nitrogen, (Widmaier et al. 2006).  
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The role of the inspiration and expiration is essential for breathing 
helping to change the intrathoracic pressure involving different muscles and to 
permit the exchange of O2 and CO2 (Schwartzstein & Parker, 2005). 
2.1. Inspiration process 
Muscular activity is involved in the inspiration process. Various muscles 
are involved, the diaphragm being the main one. Those muscles act to increase 
the thoracic volume, causing intra-pleural and alveolar pressure to fall creating 
an alveolar-mouth pressure gradient, drawing air into the lungs.  
Resting animals breathe slowly and have low flow rates. In this situation, 
the primary work of the respiratory muscles is against the compliance of the 
lungs (Cunningham & Klein 2007). However, during exercise or in response to a 
stressful situation, they may contract vigorously (West 2005) and respiratory 
muscle activity increases in order to generate an increase in minute ventilation 
(MV). In cursorial (running) mammals, ventilation is synchronized at canter and 
gallop, but not at the trot. Inhalation occurs as the forelimbs are extended and the 
hind limbs are accelerating the animal forward. Exhalation occurs when the 
forelimbs are in contact with the ground. In the galloping horse and perhaps in 
other galloping quadrupeds, much of the increase in size of the thorax during 
inhalation is a consequence of elongation of the trunk rather than an increase in 
the diameter of the thorax (Cunningham & Klein 2007). 
2.2. Expiration process 
Expiration is present at the end of inspiration. Expiration in a resting 
animal is a passive process that does not require muscle contractions (except in 
horses, where expiration is a passive – active process). Relaxation of the muscles 
contracted during inspiration permits the intrinsic elastic properties of the lungs 
and the thoracic wall to recoil to the original volume. The return to the original 
volume increases the intra-pulmonary pressure so it is greater than atmospheric, 
and air is forced out of the lungs. Forced expiration is an active process that 
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forces more air from the lungs that would occur during normal passive 
expiration. Forced expiration requires contraction of abdominal muscles to force 
viscera against the diaphragm and contraction of other muscles to pull the ribs 
caudad. Both of these actions reduce the size of the thoracic cavity and permit 
recoil of the lungs to a smaller volume than typical for resting expiration 
(Frandson et al. 2003). 
At the end of a normal exhalation, some air remains in the lungs. This air 
volume is known as functional residual capacity (FRC). At FRC, the pressure in 
the pleural cavity (Ppl) surrounding the lung is approximately 5 cm H2O below 
atmospheric pressure. Ppl decreases during inhalation as the thorax enlarges and 
the respiratory muscles perfom work to stretch the elastic lung. Resting animals 
breathe slowly and have low flow rates. In this situation the primary work of the 
respiratory muscles is against the compliance of the lungs. When the respiratory 
rate increases (e.g. during exercise), flow rates increase, and more energy is used 
to generate flow against the frictional resistance of the airways (Cunningham & 
Klein 2007).  
2.3. Gas exchange in the lungs 
The lung is the organ of gas exchange, providing the means of 
transferring O2 from the air to the blood for subsequent distribution to the tissues. 
At the same time, it enables CO2 removal from the blood which is then exhaled 
to the atmosphere. Gas exchange occurs by passive diffusion for CO2 but for O2, 
haemoglobin (Hb)-induced attraction helps a lot (Warrell et al. 2005). At rest, 
100 mm Hg pressure of O2 in the alveoli exceeds by about 60 mm Hg the 40 mm 
Hg O2 pressure in blood that enters the pulmonary capillaries. Consequently, O2 
dissolves and diffuses through the alveolar membranes into the blood (McArdle 
et al. 2006). Oxygen is poorly soluble in water and therefore in plasma. Because 
of this low solubility, most animals need an oxygen carrying pigment to 
transport sufficient O2 to the tissues. When blood in the pulmonary capillaries 
flows past the alveoli, O2 diffuses from the alveoli into the blood until the partial 
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pressures equilibrate, and there is no further driving pressure difference. Without 
Hb, which transports the majority of the O2, the cardiac output would have to be 
inordinately high to maintain the O2 supply to the body organs (Cunningham & 
Klein 2007). In contrast, CO2 exists under a slightly greater pressure in returning 
venous blood than in the alveoli causing a net diffusion of CO2 from the blood 
into the lungs. Gas exchange occurs so rapidly in the healthy lung that alveolar-
gas / blood gas equilibrium takes place in about 0.25 second or within one third 
of blood transit time through the lungs. Even in high intensity exercise, red blood 
cell velocity through a pulmonary capillary generally does not exceed by more 
than 50% its velocity at rest (McArdle et al. 2006).  
2.4. Blood flow and O2 transport 
Systemic arterial blood enters capillaries throughout the body; it is 
separated from the interstitial fluid by only the thin capillary wall which is 
highly permeable to both O2 and CO2. The interstitial fluid, in turn, is separated 
from the intracellular fluid by the plasma membranes of the cells which are also 
quite permeable to O2 and CO2. The supply of the new O2 to the alveoli and the 
consumption of O2 in the cells create partial pressure in O2 (PO2) gradients that 
produce net diffusion of O2 from alveoli to blood in the lungs and from blood to 
cells in the rest of the body (Widmaier et al. 2006).  
In the blood circulation, O2 is present in two forms: dissolved in the 
plasma and red blood cells (RBC) cytoplasm and combined to Hb molecules in 
the RBC (Wnek and Bowlin, 2008). The amount of O2 dissolved in blood is 
directly proportional to blood PO2. Relatively insoluble in water, only 3 ml of O2 
can be dissolved in 1 L of blood at normal arterial PO2 (100 mm Hg) (Widmaier 
et al. 2006). The pulmonary capillary blood equilibrates with the alveolar O2 
tension of 100 mm Hg, therefore, 0.3 ml of O2 dissolves in each decilitre of 
blood. If an animal breathes pure oxygen, the alveolar oxygen tension increases 
to approximately 600 mg Hg, and 1.8 mL of oxygen dissolves in each decilitre 
of plasma (Cunningham & Klein 2007).  
17 
 
Oxygen transport is the volume of O2 moved through the circulation in a 
unit of time. Cardiac output or blood flow to a specific site is important to O2 
transport and tissue delivery. Blood O2 content depends on the pulmonary 
capillary PO2 produced by gas exchange, the amount of Hb present, and the 
slope of O2-Hb dissociation curve (Stein, 1998). The binding of O2 is a four-step 
process, and the O2 affinity of a particular haem is influenced by the oxygenation 
of the others. This means that when the first haem unit is oxygenated, O2 affinity 
of the second haem unit is increased and so on. These haem-haem interactions 
are responsible for the sigmoid shape of the oxy-Hb dissociation curve 
(Cunningham & Klein 2007). 
 
 
 
Figure 5. O2 dissociation curve. (Printed fromo: West, J.B., 2005. Respiratory 
Physiology: The Essentials. 7th ed. Lippincott Williams & Wilkins., p76)  
 
2.5. Carbon dioxide (CO2) transport  
During steady-state conditions, approximately 80 molecules of CO2 are 
exhaled from the lungs for every 100 molecules of O2 taken up from the alveoli 
into pulmonary capillary blood (148-150 molecules). The CO2 is produced in the 
tissues and carried to the lungs through the venous blood in three forms: 
dissolved CO2, a chemical combination of CO2 and Hb and as bicarbonate 
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(HCO3-) which is the major form (90%) (Costanzo 2006). When considering 
tissue CO2 content, the difference between CO2 and O2 amounts may be as great 
as tenfold because CO2 is 23 times more soluble than O2 in plasma (Brown et al 
2006). The total atmospheric pressure is equal to 760 mm Hg; CO2 is almost 
absent in the atmospheric air, this explains the effective diffusion gradient for 
CO2 from the body to the air (Reece 2004). 
At a normal arterial PCO2 of 40 mm Hg, the amount of CO2 transported 
in solution is equal to 28 mL/L blood or equivalent to 100 mm Hg  PO2. Because 
of its higher solubility, approximately 6% of total blood CO2 is in physical 
solution compared to 1.5 % of O2 dissolved in arterial blood. The concentration 
of dissolved CO2 is greater in venous blood than in arterial blood. Rapidly CO2 
diffuses out of the cell due to its higher intracellular versus blood partial pressure 
. Once CO2 diffuses out of the cell, it quickly moves into the RBC. Once inside 
RBC, CO2 is chemically converted in the presence of water by the enzyme 
carbonic anhydrase to carbonic acid (H2CO3-) and finally into a hydrogen ion 
(H+) and HCO3- (Brown et al. 2006). 
2.6. Respiratory receptors 
Lungs contain sensory receptors that communicate with the respiratory 
centers through vagal nerve afferents. At rest, the chemical state of the blood 
exerts the greatest control on pulmonary ventilation. Variations in arterial PCO2, 
pH, PO2, and temperature activate sensitive neural units in the medulla and 
arterial system to adjust ventilation and maintain arterial blood chemistry within 
narrow limits (McArdle et al. 2006). 
Different patterns during the respiratory process need to be coordinated 
in order to avoid abnormal breathing patterns (Mc Ardle et al. 2006). Some of 
abnormal breathing patterns are tachypnea, bradypnea, apnea, and hyperapnea 
(Springhouse, 2008). Many types of receptors are involved in the respiratory 
control: chemoreceptors (central and peripheral), lung receptors (irritant, 
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pulmonary stretch, and juxtapulmonary), receptors in the chest wall, several 
receptors in the trachea, laryngeal, arterial baroreceptors, and pain receptors. 
The chemoreceptors monitor blood gas tension in arterial PaCO2, PaO2 
and pH, and helps keep MV appropriate to metabolic demands of the body. The 
chemoreceptors respond to hypercapnia (↑ CO2), hypoxia (reduction of O2), 
anoxia (absence of O2) and acidosis (↓ HCO3- or ↑ PCO2). The most sensitive 
system is the one responding to PaCO2. The central chemoreceptors are tonically 
active and vital for respiration maintenance. Eighty percent of ventilation drive 
is a result of central chemoreceptors stimulation. When they are inactivated, the 
respiration ceases. These receptors are located in the brainstem on the 
ventrolateral surface of the medulla, close to the exit of cranial nerves IX and X. 
They are anatomically separated from the medullary respiratory control center. 
These chemoreceptors respond to H+ concentrations. A rise in [H+] increases 
ventilation, while a lowering decreases it (Bijlani 2004). The peripheral 
chemoreceptors are located around the carotid sinus and aortic arch. Stimulation 
of peripheral chemoreceptors has both cardiovascular and respiratory effects. 
Peripheral chemoreceptors provide the primary site to detect arterial hypoxia and 
by reflex initiate a ventilatory response (McArdle et al. 2006).  
The carotid bodies are chemoreceptors sensitive to CO2 and O2 
concentrations in the blood (Unchoa & Cameiro, 2005). They are located close 
to the bifurcation of the internal and external carotid arteries. The latter appear to 
be most active in the foetus and of little importance in the adult. The carotid 
bodies are small, pink nodular structures with extremely high blood flow per 
gram. This high blood flow and metabolism ratio allows the carotid bodies to 
obtain their O2 needs from dissolved O2. Carotid bodies contain several cell 
types. Type I cells, or glomus cells, synapse with afferent nerves that transmit 
information back to the brain. These glomus contain a variety of 
neurotransmitters, including catecholamines, especially dopamine. Glomus cells 
are probably responsible for the chemosensitivity of the afferent nerve terminals. 
Type II cells support the axons and blood vessels that ramify within the carotid 
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body. When the carotid bodies are perfused with blood that has a low PaO2, high 
PaCO2, or low pH, firing rates in the carotid sinus nerve afferent fibers increase. 
As PaCO2 increases and pH decreases, there is an almost linear increase in 
ventilation, the response to PaO2 is non linear (Cunningham & Klein 2007). 
Peripheral chemoreceptors are sensitive to PaO2, PaCO2, pH, blood flow, and 
temperature (McGowan et al. 2003). The activity in the nerve fibers is directly 
related to the degree of hypoxia at the chemosensory cells (Kline et al. 2005). 
The carotid bodies respond to the autonomic nervous system (Koyama et 
al. 2000). The sympathetic action vasoconstricts and increases sensitivity to 
hypoxia while the parasympathetic action vasodilates and reduces sensitivity to 
hypoxia. Unlike central chemoreceptors, peripheral chemoreceptors are directly 
stimulated by blood pH (McGowan et al. 2003). The vagus contains myelinated 
afferents slowly adapting pulmonary stretch receptors which are stimulated by 
changes in lungs volumes. Stretch depolarizes these receptors, sending action 
potentials to respiratory centers in the brain via the vagal nerves (Johnson & 
Byrne, 2003). The stretch receptors are situated in the smooth muscle of the 
bronchial walls and respond to changes in transmural pressure (McGowan et al. 
2003). When these areas are excessively stretched, the information is relayed to 
the expiratory center. The center responds by shortening the duration of the 
inspiration, which decreases the risk of overinflating the respiratory structures. 
This response is known as Henri-Breuer reflex (Wilmore et al. 2008). 
The respiratory receptors do not act alone in controlling breathing. 
Breathing is also regulated and modified by the changing chemical environment 
of the body. For example, sensitive areas in the brain respond to changes in CO2 
and H+ levels. Central chemoreceptors are stimulated by an increase of H+ ions 
in the cerebrospinal fluid. The goal of respiration is to maintain appropriate 
levels of blood and tissue gases and to maintain proper pH for normal cellular 
function. Small changes in any of these, if not carefully controlled, could impair 
physical activity and jeopardize health (Wilmore et al. 2008).  
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During exercise, resting arterial Hb saturation in O2 is close to 100% in 
normal conditions (no pathology to Hb or RBC) and O2 content cannot be raised 
significantly. Oxygen delivery to exercising muscle is augmented by increasing 
muscle blood flow, made possible by metabolic vasodilatation. Oxygen 
extraction from the delivered blood is increased. Mixed venous blood has 
reduced PvO2 and increased PvCO2. Passive limb moving stimulates ventilation 
in both anaesthetized and awaken animals. This is a reflex due to receptors 
presumably located in joints or muscles. It may be responsible for the abrupt 
increase in ventilation that occurs during the first seconds of exercise (West 
2007). 
At high altitude, barometric pressure falls progressively. For instance, it 
falls from around 101 kPa (760 mmHg) at sea level to 33.6 kPa (252 mmHg) on 
the summit of Everest; however, O2 fraction remains constant at 0.209. If 
ventilation remains unchanged, reduced inspired PO2 inevitably leads to reduced 
PaO2 but PaCO2 will be unaltered (Ward et al. 2006). At such altitude, metabolic 
rate is unchanged in resting animals. Therefore increased ventilation causes a 
decrease in PaCO2. This decrease in PaCO2 inhibits ventilatory drive, which 
limits the hypoxic ventilator response by the carotid body chemoreceptors 
(Johnson et al. 2003). The RBC concentration increases and the oxyHb 
dissociation curve is shifted to the right. However, at very high altitude the very 
low PaCO2 shifts the curve to the left and the beneficial effect of increased O2 
binding in the lungs seems to outweigh the impaired O2 release in the tissues. 
The widespread hypoxia vasoconstriction in the lungs is helpful (Ward et al. 
2006). Hypoxic vasoconstriction is unique to pulmonary circulation. The 
pulmonary response is part of a self-regulatory mechanism by which pulmonary 
capillary blood flow is automatically adjusted to alveolar ventilation for 
maintaining the optimal balance of ventilation and perfusion (Dumas et al. 
1999). It increases pulmonary vascular resistance and those living at high 
altitude may develop right ventricular strain and failure (Ward et al. 2006). The 
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pulmonary vascular resistance may persist through childhood and adult life if the 
individual remains at high altitude (Rudolph 2001). 
2.7. Respiratory mechanics 
Respiratory mechanics explains how the forces generated by respiratory 
muscles cause effective ventilation of the alveoli. Resistance and compliance are 
two physical factors important in determining the relationship between pressure 
and flow in the lungs, and in the distribution of ventilation to different regions of 
the lungs. The effectiveness of ventilation not only depends on the amount of 
fresh air reaching the alveoli, but also on the matching of ventilation to blood 
flow in different regions of the lung (Johnson et al. 2003). 
2.7.1. Resistance 
Respiratory resistance is a combination of resistance to gas flow in the 
airways and resistance to deformation of tissues of both the lungs and the chest 
wall. In normal lungs, respiratory resistance is controlled by changes in airway 
diameter, mainly in small airways and bronchioles. Gas flows from a region of 
high pressure to one of lower pressure. The rate at which it does so is a function 
of the pressure difference and the resistance to gas flow. In the healthy subjects, 
the small airways only make a small contribution to total airway resistance 
because their aggregate cross-sectional area increases to very large values after 
about eight generations. Gas flow velocity and airway diameter decrease in 
successive airway generations. The airway lining will influence frictional 
resistance more with turbulent than with laminar flow, with changes in mucus 
consistency that occur in many airway diseases (Lumb 2006). The factors 
determining airway resistance are analogous to those determining vascular 
resistance in the circulatory system. Those factors include tube length, tube 
radius, and interactions between moving gas molecules. Physical, neural and 
chemical factors affect airway radii and therefore resistance. One important 
physical factor is the trans-pulmonary pressure which exerts a distending force 
on the airways, just as on the alveoli. This is a major factor keeping the smaller 
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airways, those without cartilage, to support them from collapsing. Trans-
pulmonary pressure increases during inspiration, airway radius becomes larger 
and airway resistance lower as the lungs expand during inspiration. The opposite 
occurs during expiration (Widmaier et al. 2006). 
2.7.2. Compliance 
Lung compliance is defined as the change in lung volume per unit change 
in trans-mural pressure gradient. There are two major determinants of lung 
compliance; first, the stretchability of lung tissues (particularly their elastic 
connective tissues, thus, a thickening of the lung tissues decreases lung 
compliance) and the other is the surface tension at the air-water interfaces within 
the alveoli. The surface of the alveolar cells is moist, so the alveoli can be 
pictured as air-filled sacs lined with water. At an air-water interface, the 
attractive forces between the water molecules, known as surface tension, make 
the water lining like a stretched balloon that constantly tries to shrink and resists 
further stretching. Thus, expansion of the lung requires energy not only to stretch 
the connective tissue of the lung, but also to overcome the surface tension of the 
water layer lining the alveoli (Widmaier et al. 2006). Compliance is usually 
expressed in L or mL per KPa or cmH2O. The normal value of compliance is 
approximately 1.5 L.kPa-1 or 150 mL.cmH2O-1. When an increase of 
peribronchial and perivascular fluid and thickening of the lung tissues occurs for 
instance, a decrease in lung compliance is observed (Lumb 2006), a condition 
called as stiff lungs.  
Elastic recoil is expressed as elastance, which is the reciprocal of 
compliance. Only a quarter to a third of the lungs elastic recoil is caused by the 
elastic fibres of its alveolar walls, most is caused by surface tension at the 
alveolar tissue (Bray et al. 1999). Respiratory system elastance is known to 
increase with frequency breathing, and tissue resistance is known to decay 
hyperbolically over the range of physiological breathing frequencies, whereas 
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airway resistance remains fairly constant both in healthy and mildly constricted 
lungs (Lutchen et al. 1994). 
2.7.3. Ventilation and Lung Mechanics 
Breathing is caused by rhythmic contractions of skeletal muscles that are 
entirely dependent upon intact nervous connections from the medulla through 
the spinal cord, the phrenic and intercostal nerves. Breathing is thus the product 
of chemical and neural influences on a network of neurones, motor nerves, and 
muscles; the result being dependent on the mechanical properties of the chest, 
the lungs, and the airways (Whipp 1987). The act of breathing is performed 
against several impediments: elastic, resistive, visco-elastic, plasto-elastic, 
inertial and gravitational forces, compressibility of intra-thoracic gas, and 
distortion of the chest wall (Polese et al. 2005).  
Ventilation is defined as the exchange of air between the atmosphere and 
alveoli. Like blood, air moves by bulk flow, from a region of high pressure to 
one of low pressure. In the respiratory system, pressures are expressed in relation 
to atmospheric pressure, which is 760 mmHg at sea level (West 2008). During 
ventilation, air moves into and out of the lungs because the alveolar pressure is 
alternately less than and greater than atmospheric pressure (Widmaier et al. 
2006).  
The intrapleural pressure causes the lung and thoracic wall to move in 
and out together during normal breathing (Widmaier et al. 2006). When the 
thorax expands and pull the lungs, they must comply and expand. The air must 
comply and smoothly flow to the alveoli. If the thorax and lungs are stiff or the 
airways are narrow, so the air does not move in and out of the lungs freely, 
pulmonary ventilation will be impaired (Sabyasachi 2007). 
2.7.4. Elastic properties of the lungs 
The elastic properties of the lung and of the chest wall to airflow 
resistance are part of the mechanic of breathing. The lung is a volume-elastic 
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container that tends to deflate itself. The deflation force exerted by the lungs is 
call elastic recoil pressure. This pressure increases with lung volume and the 
pressure requires maintaining inflation equals to the elastic recoil. Lung 
expansion is maintained either by negative pleural pressure at the outer surface 
of the lung or by positive pressure applied by the airway opening to the inner 
surface of the lung (Shields et al. 2004). 
The movements of the lungs are entirely passive and result from forces 
external to the lungs. The pattern of lung response is governed by the physical 
impedance of the respiratory system. The most important impedances are: elastic 
resistance of lung tissue and chest wall, resistance from surface forces at the 
alveolar area, frictional resistance to gas flow through the airways, frictional 
resistance from deformation of thoracic tissues, and inertia associated with 
movement of gas and tissue. The surface forces have a predominant influence on 
the elastic properties of the lung at volumes higher than functional residual 
capacity, which implicates alveolar size as the major determinant of specific 
pulmonary elastance for a constant number of alveoli (Haber et al. 1983). 
2.7.5. Pulmonary Volumes and Capacities 
The volume of gas in the lungs can be divided into the following 
components:TLC, VC, IC, ERV, IRV, TV, RV and FRC (Fig 5). A capacity is 
defined as the summation of two, or more, volumes. From these variables, the 
most commonly used to test respiratory function are TV (amount of air breathed 
in or out during a quiet breathing), RV, VC and FRC. Those can be useful in 
diagnosing certain pulmonary diseases (Johnson et al 2003). Pulmonary volumes 
are either associated with the amount of air within them at any time or with the 
amount associated with breath (Reece 2004). 
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Figure 6. Respiratory volumes and capacities. Printed from 
(http://images.google.ca/imgres?imgurl=http://faculty.stcc.edu)  
 
The O2 needs of metabolism require that an animal take a certain volume 
of air into its lungs, essentially its alveoli, each minute. The total volume of air 
breathed per minute or MV (minute ventilation), is determined by the volume of 
each breath, known as the tidal volume (TV), and the number of breaths per 
minute, know as respiratory frequency or RR (respiratory rate). 
MV = TV × RR 
The increase in MV, which must occur when an increase in metabolic 
rate demands more oxygen, can be brougth about through an increase in TV, RR 
or both. The IRV is the amount of air that can still be inspired after inhaling the 
TV, and ERV is the amount of air that can still be expired after exhaling the TV 
(Johnson et al. 2003). The RV is the amount of air remaining in the lungs after 
the most forceful expiration. The TLC is the sum of all volumes while VC is the 
sum of all volumes over and above the RV, which is also the maximum amount 
of air that can be inspired after the most forceful expiration; IC is the sum of TV 
and IRV, and FRC is the sum of ERV and RV (Reece 2004). Normal lung 
volumes provide lessons about respiratory physiology in healthy individuals. 
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The TLC is more than ten times larger than the normal TV, so there is a 
tremendous reserve capacity for increased ventilation with increased O2 demand 
or reduced supply. This is part of the reason why pulmonary gas exchange is 
usually not a limiting factor in O2 uptake at sea level in anyone except highly 
trained elite athletes (Johnson et al. 2003). Finally, FRC is the volume of air 
present in the lungs at the end of passive expiration (Sabyasachi  2007). A 
lowered or elevated FRC helps to diagnose some forms of respiratory disease.  
2.7.6. Dead space 
The anatomic dead space is the volume of the upper respiratory system 
where  gas exchange do not occur. Dead space (Vs) can also be present within 
the alveoli. This alveolar dead space is caused by alveoli that are poorly perfused 
with blood, so that gas exchange cannot occur optimally. Physiological dead 
space is the sum of the anatomic and the alveolar dead space (Cunningham & 
Klein 2007). The strict definition of the anatomical dead space is the volume of 
an inspired breath which has not mixed with the gas in the alveoli. Because gas 
exchange effectively only takes place in the alveoli there is no CO2 excreted into 
the dead space (Davies & Moore 2003). Essentially, all the gas exchanges 
between air and blood take place at the alveolar surface. At the end of the 
inspiration, the content of the alveoli has been diluted by inspired room air, 
which now also fills the anatomical dead space. At the end of expiration, the 
anatomical dead space is filled with alveolar air, and this partly used air is 
inhaled first in the next inspiration (Fig. 6) (Davies & Moore 2003). Not all of 
the air entering the respiratory system actually reaches the alveoli and takes part 
in gas exchange.  
 
Figure 7.  Anatomic and alveolar dead space  
(Printed from http://img.tfd.com/vet/thumbs/gr356.jpg ) 
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The structures included in the dead space are: nose and mouth, pharynx, 
larynx, trachea, bronchi and bronchioles, down to and including the terminal 
bronchioles. The fraction of each breath ventilating the dead space is known as 
the VD/TV ratio. The VD/TV varies considerably among species. In smaller 
species, such as dogs, it approximates 33%, whereas in some larger species, such 
as cattle and horses, it approximates 50% to 75%. Because the volume of the 
anatomic dead space is relatively constant, changes in TV, RR or both can alter 
the relative amounts of air that ventilate the alveoli and the dead space. These 
changes in TV and RR occur in animals during exercise and thermoregulation. 
For example, the small TV and high RR characteristic of panting in dogs cause 
more air to ventilate the dead space in order to cause water evaporation and heat 
loss. Cattle, pigs and mules subjected to heat stress also increase RR and dead 
space ventilation when trying to lose heat. In contrast to the effects of heat stress, 
cold stressed animals have a higher metabolic rate, which is necessary to 
maintain body temperature in cold conditions. This leads to an increase in both 
O2 consumption and CO2 production, making it necessary for the animal to 
increase alveolar ventilation and decrease dead space ventilation. Reducing the 
RR and increasing TV accomplish the latter adaptations (Cunningham & Klein 
2007). 
Anatomical dead space can be measured using Fowler’s method which is 
based on the single breath nitrogen test (McGowan et al. 2003). This test 
measures inequalities of ventilation, useful to evaluate ventilatory capacity 
(West 2007). If some regions of the lung expand before others in the process of 
inspiration, they will receive inappropriately large parts of this dead space, and 
the regions receiving air later in inspiration will receive more fresh air. This type 
of dead space is called anatomical dead space because it measures the 
anatomical volume of the conducting airways. If each acinus or end respiratory 
unit was perfect, the amount of air received by each alveolus would be matched 
by the flow of blood through the pulmonary capillaries. In a normal healthy 
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person, anatomical and physiological dead space are almost equal, alveolar dead 
space being very small (<5 mL). However, the volume of alveolar dead space 
increases when lung disease alters ventilation / perfusion matching,. 
Physiological dead space is calculated, using the Bohr Equation (McGowan et al 
2003). The Bohr Equation permits the determination of the sum of the anatomic 
and the alveolar dead space. It evaluates the measurable volume of CO2 found in 
the mixed expired gas coming from the alveoli. The PCO2 of the collected mixed 
expired gas can be determined with a CO2 meter. The CO2 meter is also often 
used to estimate the alveolar PCO2 by analyzing the gas expelled at the end of a 
normal tidal expiration, the end tidal CO2 (Levitzky 2007). 
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3. SAFETY PHARMACOLOGY 
Safety Pharmacology is the discipline trying to predict whether a drug, if 
administered to human (or animal) population, is likely to be found safe (Pugsley 
et al. 2008). It is, with the primary pharmacodynamic studies which are those 
evaluating the mode of action and/or effects of a substance in relation to its 
desired therapeutic target and secondary pharmacodynamic studies which 
evaluate the mode of action and/or effects of a substance not related to its 
desired therapeutic, a part of the pharmacology discipline (FDA 1997). 
The origins of Safety Pharmacology are grounded upon observations that 
organ functions can be toxicological targets in humans but the effects cannot be 
readily detected by standard toxicological testing (Mortin et al. 1997; Williams 
1990; Zbinden, 1984). The objectives of safety pharmacology are: 1) to identify 
undesirable pharmacodynamic properties of a substance that may have relevance 
to its human safety; 2) to evaluate adverse pharmacodynamic and/or 
pathophysiological effects of a substance observed in toxicology and/or clinical 
studies; and 3) to investigate the mechanism of the adverse pharmacodynamic 
effects observed and/or suspected (ICH 2001). 
The term first appeared in drafts of the ICH in 1997 (Bass et al 2004).  
Following that, in 1999, an Expert Working Group was formed and began their 
work to define the guidelines of Safety Pharmacology. A harmonized Safety 
Pharmacology guideline was finalized and adopted by the regional regulatory 
authorities over 2000–2001 (ICH 2001). They describe their implications in 
studies of the three vital systems: central nervous, cardiovascular and respiratory 
systems (Porslot et al. 2002). 
Those guidelines were accepted in United States, Europe and Japan. Prior 
to 1990’s, toxicological testing done on lead compounds was limited and did not 
allow to identify all adverse effects produced  by those compounds. The U.S. 
and European regulations provided only general references to the evaluations of 
drug effects (Kinter et al 1994; Lumley, 1994).  
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Organ function assessments were inconsistent and often viewed as unimportant 
(Green, 1995; Proakis, 1994). In fact, during that period, it was discovered that 
some of those compounds showed rare and potentially lethal adverse effects later 
in the testing process (Pugsley et al. 2008).   
The organ systems and functions most frequently responsible in these 
events were the cardiovascular, central nervous and renal systems, The result 
was almost always a critical care emergency (Kinter et al 1994). Such episodes 
contributed to the development of Safety Pharmacology. 
The ICH guidelines have brought uniformity to the evaluations of new 
drugs for effects on organ functions (Bass et al. 2004). Within a short period, 
Safety Pharmacology had evolved into a discipline designed to bridge the gap 
between preclinical toxicology and preclinical and clinical drug development 
(Bass et al. 2004). However the creation of Safety Pharmacology has not 
resolved all problems with respect to detection of rare and lethal adverse effect 
liability and more problems have to be solved in order to quantify, with high 
certainty, a risk/benefit assessment of a new drug (Pugsley et al. 2008).  
Its future will depend, in part, upon the scientific and technological 
advances and regulatory challenges that envelop pharmaceutical development 
The scientific challenge facing Safety Pharmacology is to keep pace, to adapt, 
and to incorporate new technologies in the evaluation of new drugs in 
nonclinical models and identifying the effects that pose a risk to human 
volunteers and patients (Bass et al. 2004).  
It was suggested to evaluate the respiratory system using different 
methodologies assessing RR and other measures of respiratory function (e.g. 
TV) or Hb  saturation in O2 (ICH 1997). To obtain reliable results, it is important 
to reduce to a minimum the potential effects of exterior factors that may affect 
the response of the animals. It was suggested by Savoie (1982), to use non-
invasive methods since these methods are less stressful on the animals and do 
not require anaesthesia, analgesia or tranquilizer. 
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3.1. Non-invasive methods  
3.1.1. Spirometry 
Spirometry is the measurement of airflow into and out of the lungs 
(Wagner et al. 2006). It measures air movement and results are expressed in 
volume (Lumb 2006). It is the most common method used to evaluate lung 
function (Wagner et al. 2006). It is inexpensive, convenient, and easy to 
perform. It is used to determine among other things VC, the forced vital 
capacity, the forced expiratory volume (FEV), the peak expiratory flow rate, and 
the FEV at 25-75% of the volume expired. 
The technique is widely used in humans for the diagnosis of lung disease, 
monitoring, evaluation of disability, or for public health surveys (Lockey et al. 
2000). It is less suitable for animals as it requires subject cooperation (Coffman 
and Hessel, 2005). In spite of that difficulty, it has been used in animals for 
many years as a research tool. As early as 1923, spirometry was used in studies 
of energy metabolism in farm animals (Orr & Magee, 1923). It was also used in 
sheep (Edward, 1966), calf (Blaxter et al. 1953, Bureau et al. 2001), dogs 
(O’Toole et al. 2001) and cats and rabbits (Bartlett, 1957). 
More recently it has been used in rodent to study for the development of 
rodent models of sulfur mustard-induced pulmonary injury (Weber et al. 2010). 
In anesthetized rodents, the possibility of using a two-sidearm tracheal cannula 
for measurements of respiratory airflow was investigated by Mortola and 
Noworaj (1983). This procedure appeared to be a suitable and very practical way 
of measuring mean airflow and tidal volume in anesthetized small animals, 
ranging in size from newborn rats to newborn puppies. 
3.1.2. Body plethysmography 
Recent emphasis on the benefits of noninvasive technology has renewed 
interest for the use of body plethysmography, among other things to analyze 
expiratory tidal flow patterns as a tool to assess airway obstruction. The main 
advantage of this approach is its non-invasiveness, allowing simple, rapid, and 
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repeatable measurements of several conscious animals at a time (Hantos & 
Brusasco 2002). 
The whole-body plethysmography method is a non-invasive method to 
measure the respiratory function. Emka Technologies (Emka Technologies, 
USA, 307 Annandale Road, Falls Church, VA 22042, USA) has developed a 
system that can be used in freely moving laboratory animals such as rodents, 
guinea pigs, rabbits, dogs, pigs and monkeys. The manufacturer can also produce 
a modified system to allow evaluating respiratory parameters in conscious 
restrained or anesthetized rodents as well as in guinea pigs. 
The plethysmograph has two chambers, each fitted with a 
pneumotachograph. The subject is placed in one of them (subject chamber) and 
the other remains empty (reference chamber).  
A modification of the whole body plethysmography, the head out 
plethysmography, has also been used. Animals are gently placed in the body 
plethysmographs while the head of each animal protrudes through a neck collar 
into a ventilated head exposure chamber (Glaab 2007). The procedure has been 
used in sheep (Bedenice et al. 2004). Aerosols can be delivered directly through 
the head exposure chamber. Tidal flow measurement is made with a calibrated 
pneumotachograph and a differential pressure transducer attached to the top port 
of each body chamber. The amplified and digitized flow signals are integrated 
with time to obtain TV. From these signals several standard respiratory 
parameters, including TV, RR, consequently MV, time of inspiration and 
expiration, and mid-tidal expiratory flow (EF50) can be derived from software 
analysis. The non-invasive measurement of EF50 was first described as an 
appropriate instrument to measure airway responsiveness in conscious mice by 
Vijayaraghavan et al. (1994). Moreover, EF50 is based on physiological 
principles and has a physical meaning [mL/s] that is directly related to airway 
resistance, thus enabling quantitative interpretation of airway changes between 
animals (Hantos et al. 2002). 
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The barometric plethysmography has been also used to study respiratory 
parameters. The procedure has been described by Jacky (1978). In that 
procedure, the subject rests in an environmental chamber, and respiration is 
indicated by barometric pressure oscillations proportional to tidal volume. It has 
been used in mice (Hamelmann et al. 1997; Vijayaraghavan et al. 1994), in rats 
(Johanson &Pierce 1971, Hamelmann et al. 1997), in guinea pigs (Pennock et al. 
1979), and in monkeys (Twenhafel et al. 2009). 
Plethysmography has an advantage over other procedures such as the gas 
dilution methods which fail to record the volume of any gas that may be trapped 
in an isolated compartment inside the lung, and therefore give a false-low value 
of FRC. During plethysmography, values are unaffected by such trapped gases 
(Sabyasachi 2007).  
3.1.3. Pneumotachometry  
Pneumotachometry is a procedure most commonly used to monitor 
ventilation during acute illness in human (Cannon et al. 2000). The most 
commonly used devices for this purpose are the Fleish and the Silvermann 
pneumotachometers, which function by creating a very slight resistance to air 
flow. Pressure differential across this resistance is proportional to, and in phase 
with, the speed of air movement (Waterhouse   2005). The flow sensing device is 
positioned in the mouth and the flow signal is integrated over time to compute 
volumes. The Fleish pneumotachometer remains the reference instrument but 
does not always cover the entire range of flows to be measured. Major 
advantages of pneumotachometers are their compactness and their possible use 
with an open breathing circuit. They are easier to use and to decontaminate than 
spirometer and are gradually replacing those (Hans-Ulrich & Bankier 2003). 
3.1.4. Oscillometry 
Forced oscillometry is a very attractive method because it is non-invasive 
and appears to be more sensitive to changes in lung functions than are 
35 
 
measurements of dynamic compliance and total pulmonary resistance. Flow and 
pressure are measured at the nares in response to impulses applied to the 
respiratory system (McGorum et al. 2007). It determines breathing mechanics by 
superimposing small external pressure signals on the spontaneous breathing of 
the subject (DuBois et al. 1956). Forced oscillometry is indicated as a diagnostic 
method to obtain reliable differentiated tidal breathing analysis. 
The ability to measure lung function in similar ways in human and 
monkey studies is a particular advantage (Coffman & Hessel  2005). In primates 
the non-invasive forced oscillation technique is the preferred technique for 
measuring changes in pulmonary function (Gundel et al. 1992). This technique 
superimposes forced oscillations onto normal spontaneous breathing either at the 
airway opening or at the body surface, and measures respectively input or 
transfer impedance, from which airway resistance and compliance are calculated 
(Madwed & Jackson, 1997). In humans, the forced oscillation technique is used 
with subjects unable to cooperate, such as very young children, and for specific 
research purposes (Oostveen et al. 2003). Potential applications of oscillometry 
include paediatric, adult, and geriatric populations, comprising diagnostic 
clinical testing, monitoring of therapeutic regimens, and epidemiological 
evaluations, independent of severity of lung disease (Smith & Goldman 2005). 
The technique has also been used in various animal species. In horses 
(Erck et al.  2003, 2004; Klein et al. 2006), it was, for instance, more sensitive  
than the oesophageal balloon method which is the conventional reference 
technique, for pulmonary function testing (Erck et al. 2003). It seems to be a 
practical and non-invasive pulmonary function test that may be useful in 
assessing subclinical changes in horses (Erck et al. 2004; Reinhold et al. 1996). 
In new born calves, it was successfully used to evaluate their respiratory 
adaptation to extra-uterine life during the first 24 hours (Uystepruyst et al. 
2000).  It was also used in lamb (Pillow et al. 1996), dogs (Clercx et al. 2003), 
rabbits, (Peslin et al. 1994), guinea pigs (Sobh et al. 1997) and rats (Thamrin et 
al. 2005). 
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3.2. Invasive methods 
Direct measurement of pleural pressure requires placement of a catheter 
in the pleural cavity. Fortunately, oesophageal pressure also provides an accurate 
estimate of pleural pressure (McGorum et al. 2007). Measurement of 
oesophageal pressure is a practical approach to measuring changes in 
intrathoracic pressure, for the evaluation of respiratory system mechanics in the 
assessment of pulmonary physiology and pathophysiology. The pressures across 
the lungs and chest wall can be measured, and these measurements, together 
with volume and flow, allow the respiratory system resistance and compliance to 
be partitioned into their pulmonary and chest wall components. Several 
approaches can be used to make measurements, including air-filled balloon 
catheters, liquid-filled catheters, and small transducers placed in the oesophagus 
(Murphy et al. 1998). When the subject is relaxed or under local anaesthesia, the 
catheter is carefully inserted through the nostril. When the subject feels that the 
tip of the device is touching the pharynx, a mouthful of water should be 
swallowed. The test consists of occluding a subject’s airways at end-expiration 
while measuring oesophageal pressure and airway opening pressure during three 
to five spontaneous inspiratory efforts. (Qutayba et al. 2005).  
Another approach for invasive assessment of airway function in rodents is 
the low-frequency forced oscillation technique. The procedure was derived from 
similar techniques used in humans and larger animals. It gives estimates of lung 
impedance, which can be considered the most detailed measurement of 
pulmonary mechanics currently available (Peslin & Fredberg 1986).  
 
4. POSITIVE CONTROL PHARMACEUTICAL SUBSTANCES  
Pharmaceutical substances with known effects were used as positive 
controls. Those substances included: albuterol, metacholine and remifentanil. It 
appears important in the literature review to present a summary of their 
respective pharmacology. 
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4.1. Albuterol 
Albuterol is a selective ß2-adrenergic agonist with pharmacological 
properties and therapeutic indications. It is administered either by inhalation or 
orally for the symptomatic relief of bronchospasm. When administered by 
inhalation, it produces significant bronchodilation within 15 minutes and effects 
are demonstrable for 3 to 4 hours (Hardman et al. 1996). Inhalation of a ß-
adrenergic agonist is clearly the preferred therapy for bronchoconstriction per se 
(Fanta et al. 1986). Beta-adrenergic agonists are the only agents shown to be 
immediately effective in the setting of acute, severe asthma.  
4.2. Methacholine 
Methacholine chloride (acetyl-â-methylcholine) is a 
parasympathomimetic synthetic analog of acetylcholine. It stimulates muscarinic 
postganglionic parasympathetic receptors, causing bronchial smooth muscle 
constriction (Birnbaum & Barreiro 2007). Used by inhalation in humans for the 
diagnosis of bronchial hyperreactivity in asthma (Tulic et al. 1999) or chronic 
obstructive pulmonary disease, it is also recognized to induce reflex 
bronchoconstriction when administered into the bronchial artery (Wagner & 
Jacoby 1999).  
Methacholine has a more prolonged action than acetylcholine because it 
is hydrolyzed by acetylcholine esterase at a considerably slower rate and is 
almost totally resistant to hydrolysis by nonspecific cholinesterase. Its selectivity 
is manifested by slight nicotinic and a predominance of muscarinic actions, the 
latter being most marked on the cardiovascular system (Hardman et al. 1996).  
4.3. Remifentanil 
Remifentanil is a potent opioid selective for µ-opioid receptors that 
produces intense analgesia very rapidly. It shares with other opioids respiratory 
depression, bradycardia, skeletal muscle rigidity, and reversibility by naloxone. 
In contrast to other short-acting opioids, remifentanil contains an ester linkage 
and so is metabolized by circulating and tissue nonspecific esterases (Hardman 
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et al. 1996). As a result, recovery time from remifentanil is rapid and almost 
independent of dose or duration of infusion (Egan et al. 1993). 
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Abstract: 
This study compares basic respiratory variables (rate, tidal and minute volumes) 
with time-, flow- and ratio-derived parameters obtained using head-out 
plethysmography in rats following administration of reference drugs (isotonic 
saline, 2.0 mL/kg, IV; albuterol, 400 µg/kg, inhalation; methacholine, 136 µg/kg, 
IV; and remifentanil, 14 µg/kg, IV) to identify respiratory variables with 
superior sensitivity. Paired t-tests by block-period, and analysis of covariance 
(ANCOVA) with baseline as covariate and a posteriori pair-wise comparisons 
using Dunnett’s test were used. Variations in respiratory parameters observed 
over time justify the use of a control group in any respiratory safety 
pharmacology study for inter-groups comparison. Handling-, and slumbering-, 
induced perturbations were minimal. The system was sensitive and specific to 
detect changes in respiratory variables related to pharmacologically-induced 
bronchodilation, bronchoconstriction and central respiratory depression. The 
standard variables (respiratory rate, tidal and minute volumes) confirmed to be 
the cornerstone of respiratory safety pharmacology to detect pharmacological 
changes. Flow-derived parameters appeared as highly valuable complement for 
interpretation of respiratory response, whereas time- and ratio-derived 
parameters presented limited added value during interpretation. 
 
Key words:  ICH S7A, Rat, Conscious, Respiratory function, Monitoring 
qualifications, Validation. 
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1. Introduction 
The respiratory system is assessed during safety pharmacology studies based on 
regulatory requirements for drug safety testing (Anon., 2001). The rat model is 
the preferred species in most drug development programs (Lindgren et al., 2008) 
with regards to its high genetic homogeneity, lower test material requirements, 
and abundant historical data. Various non-invasive and invasive methods are 
used to evaluate the effects of test substances on the respiratory function 
(Murphy et al., 1998; 2001; Sommer et al., 1998; Walker et al., 1997). Among 
these methods, plethysmography (Hoymann, 2007), pneumotachometry (Davies 
and Dunster, 2002), oscillometry (Hoffman, 2002), and esophageal 
catheterization (Eng et al., 1990) are used based on the various experimental 
requirements.  
Minimizing the potential effects of external factors that may affect animal 
response is critical to obtain reliable respiratory data. Savoy et al. (1982) 
suggested the use of non-invasive methods which are less stressful to animals 
and do not require anesthesia, analgesia, or sedation. Head-out and whole body 
plethysmographs are accepted non-invasive respiratory monitoring 
methodologies and are widely used in safety pharmacology. The head-out 
plethysmograph is simple to use, and allows nearly natural breathing pattern 
(Hoymann, 2006). Recently, we have reported the effects of reference drugs on 
basic respiratory variables [tidal volume (TV), respiratory rate (RR), and minute 
ventilation (MV)] monitored with head-out plethysmograph in rats (Authier et 
al., 2009).  
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Validation of test systems is a process involving three qualifications tiers, 
namely installation (IQ), operational (OQ) and performance (PQ) qualifications. 
The accuracy of a measurement system is the degree of closeness of 
measurements of a quantity to its actual (true) value. Accuracy is usually 
provided by the supplier and is verified during IQ/OQ, which were outside of the 
scope of the present work. Regulatory considerations of the validation process 
(FDA, CFR 21 Part 11: electronic records and electronic signatures) were also 
outside of the focus of the current discussions. By conducting the PQ, our 
scientific interests were to test precision, i.e. repeatability and reproducibility, as 
well as sensitivity and specificity of the test system in the conditions that 
prevailed during the study. Therefore, the aims of the PQ evaluation were, 
respectively, 1) to determine the within-time stability of respiratory 
measurements before and after saline-placebo (negative drug, i.e. without any 
expected respiratory effect) administration with stable head-out 
plethysmography environmental conditions; to administer reference drugs (saline 
and positive drugs with known effects on the respiratory system) to conscious 
male Sprague-Dawley rats in order to test 2) inter-individuals reproducibility; 
and 3) concurrent validity. Criterion (concurrent) validity is a measure of how 
well one variable or set of variables predicts an outcome based on information 
from other variables. Concurrent validation was assessed by comparing basic 
respiratory variables (RR, TV, and MV) with time-, flow- and ratio-derived 
parameters to identify variables with superior sensitivity or affected specificity. 
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2. Materials and methods 
2.1. Statement on use and care of animals and regulatory compliance  
During the study, care and use of animals were conducted in accordance with 
principles outlined in the current Guide to the Care and Use of Experimental 
Animals published by the Canadian Council on Animal Care (CCAC) and the 
Guide for the Care and Use of Laboratory Animals published by the U.S. 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). LAB 
Research, Inc.’s facility is CCAC and Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) accredited. 
All procedures were reviewed and approved by the Institutional Animal Care 
and Use Committee before study initiation. Data were obtained under studies 
conducted in accordance with the Good Laboratory Practice (GLP) regulations 
of the United States Food and Drug Administration (21 CFR Part 58 and 
subsequent amendments).  
2.2. Animal housing 
The experimental population comprised thirty-two (32) specific pathogen-free 
male Sprague-Dawley rats (242–315 g, 59–65 days). Animals were obtained 
from Charles River (St-Constant, QC, Canada) and were group-housed (2-3 
animals per cage) in polycarbonate cages equipped with filter top and water 
bottles. They were fed ad libitum with standard certified commercial rodent 
chow (Teklad Certified 18% Lab Rodent Diet #2018C) and provided with 
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reverse osmosis water. The animal room environment was controlled (targeted 
ranges: temperature 18-24°C, humidity 30–70%, 12 h light/12 h dark, 10–15 air 
changes/h). Temperature and relative humidity were monitored continuously. 
2.3. Respiratory monitoring system 
Respiratory variables were continuously recorded at a sampling frequency of 
200 Hz. Respiratory function was monitored using head-out plethysmographs 
(Model PC-H2, SCIentific Respiratory Equipment Quebec (SCIREQ) Inc., 
Montreal, QC, Canada) with opaque headrest connected to a pneumotachometer 
(Model 8420 with a 5 L/min capacity, Hans Rudolph, MO, USA). The headrests 
were such that the nose of the rat was open to ambient air, but visual and 
auditory stimulations were attenuated, providing a more comfortable 
environment for the animals as supported by the regular breathing patterns 
observed and decreased resistance to the restraint in the plethysmograph. 
Airflows from rat pneumotachometers were monitored using differential 
pressure transducers (Model UT-PDP-02, 0.2 kPa nominal, SCIREQ Inc., 
Montreal, QC, Canada) connected to the plethysmographs and to the data 
acquisition matrix (In expose-08, Data Acquisition Controller 8 channels, 
SCIREQ, Inc., Montreal, QC, Canada) and a real-time respiratory analyzer 
(flexi-Ware 5.3.1, SCIREQ, Inc., Montreal, QC, Canada) software installed on a 
computer (Model PU-2.5 OptiPlex 745 Workstation, Dell, Dallas, TX, USA). 
2.4. Positive and negative control drugs 
Isotonic saline (0.9% sodium chloride, Baxter, ON, Canada), 400 μg/kg 
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albuterol (Ratiopharm, Inc., QC, Canada), 136 μg/kg methacholine (Sigma-
Aldrich, ON, Canada) and 14 μg/kg remifentanil (Ultiva, Abbott Laboratories 
Ltd., ON, Canada) were administered to conscious rats, at doses selected based 
on historical data, to induce moderate to severe respiratory effects (Authier et al., 
2008; 2009). 
Dose volumes for all intravenous agents were 2.0 mL/kg (all intravenous 
agents), and administered by tail vein injection using a butterfly catheter. 
Albuterol was administered by inhalation via a pressurized metered-dose inhaler 
with a holding chamber and mask. All administrations were performed with 
minimal handling to minimize interferences..  
2.5. Experimental design 
Animals were randomized based on body weight using assigned random 
numbers (Microsoft Office Excel 2003). A total of 8 animals in each group were 
dosed on 4 consecutive days. All animals (n=8) receiving the same treatment 
were dosed the same day. The treatment order was assigned to systematically 
change the sequences. 
Body weight was recorded prior to randomization and on the dosing day. All 
animals were acclimated to the head-out plethysmograph restraint unit with 
opaque headrest. The animals were acclimated in the head-out plethysmograph 
for 4 days with increasing durations up to 2 1/2 h. 
Within 30 min after animals were placed in the plethysmograph, pulmonary 
monitoring was initiated to establish pre-dosing baseline. After at least one hour 
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of baseline monitoring, animals were temporarily removed from the 
plethysmograph for dosing. Following dosing, animals were returned to the 
plethysmograph and pulmonary monitoring was continued for a period of 
approximately four hours. Data were collected continuously for the following 
eleven variables: RR, TV, MV, inspiratory time (IT), expiratory time (ET), time 
to peak expiratory flow, peak inspiratory flow, peak expiratory flow, mid-tidal 
expiratory flow (EF50), inspiratory:expiratory (I:E) ratio, and inspiratory to total 
breath (I:TB) ratio. At the end of the recording period, animals were returned to 
their cages. 
2.6. Statistical Analysis 
Data were continuously monitored at 200 Hz and were averaged in single 5 min 
block of data for the control and treated groups. The averaged data were grouped 
in four different blocks: block 1 (0-30 min pre-treatment), block 2 (31-60 min 
pre-treatment), block 3 (0-120 min post-treatment) and block 4 (121-240 min 
post-treatment). Data from each block were compared using repeated measures 
general linear model. A priori contrast analysis for each drug was conducted 
using a paired t-test based on values averaged during 60 min (12 measures at 5-
min interval) prior to dosing, and up to 4 h (48 measures at 5 min interval) post-
treatment. Finally, a repeated measures two-way analysis of covariance 
(ANCOVA) with baseline score as a covariate, comparing saline to positive 
drugs, was performed to detect intergroup difference, with a posteriori pair-wise 
comparisons using Dunnett’s test (Vickers, 2001). A limitation of the study 
design was the use of the same control group with IV administration for the three 
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treated groups including albuterol, which was given by inhalation. We assumed 
that inhalation and IV administration would have comparable effects on the 
respiratory variables per se. 
 Alpha threshold was set at 0.05, mean (SD) values (except when difference is 
notified) are presented, and SAS version 9.1 for Windows (SAS Institute, Inc., 
Cary, NC, U.S.A.) was used (Littell et al., 2006). The analysis initially included 
standard respiratory parameters, RR, TV, and MV, followed by the three time-
derived variables, the three flow-derived variables, and the two ratios. 
Characterization of stability (or consistency between repeated measures under 
the same conditions) was based on data provided from the placebo group (n=8). 
Therefore, within-time repeatability was assessed in the placebo group before 
(pre-dosing period) and after saline administration. Stability was also tested 
during the pre-dosing period of the drug treated groups. Inter-individuals 
reproducibility, or test system responsiveness, was tested by systematically 
evaluating the individual response to positive drug administration. Maximal 
percentages of change were calculated from the average value for each variable 
measured during the pre-treatment period. Concurrent validity focused on the 
response obtained with RR, TV and MV compared with other variables. 
Sensitivity and specificity were assessed by comparing the response obtained 
with these three variables and the parameters of interest using all-or-none binary 
estimation. 
 
 
49 
 
 
3. Results 
3.1. Saline 
None of the respiratory parameters monitored showed statistically significant 
difference within the pre-treatment period, or between the pre-treatment period 
and the first two hours post-treatment with saline (block 3). However, RR 
(p<0.0001) and MV (p=0.003) significantly decreased during the last two hours 
post-treatment (block 4) when compared to the pre-treatment period. A 
compensatory increase in TV (p=0.03) was observed over the same period. 
Parallel to the decrease in RR, all three within breath time variables, IT 
(p<0.0001), ET (p=0.004), and time to peak expiratory flow (p<0.0001), 
significantly increased. If peak inspiratory flow significantly (p=0.002) 
decreased during block 4, this was not the case for peak expiratory flow and 
EF50. Both I:E and I:TB ratios slightly but significantly decreased during block 
4 (p=0.02).  
When post-treatment measures were compared to the pre-treatment averages, an 
increase in TV (Fig. 1) and MV was observed at the first time-point post-dosing 
(T5 min). The decreases in RR (-19%) and MV (-18%) noted during block 4 
were mainly related to the values collected around T210 min post-dosing. 
Alteration of the three times variables (+55% in IT at T220; +19% in ET at 
T210; +48% in time to peak expiratory flow at T220), peak inspiratory flow (-
21% at T210), and on both ratios (+41% in I:E and +8% in I:TB at T220) were 
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noted at the same time point. Seven out of 8 rats presented the same pattern, 
suggesting that this was a reproducible phenomenon. 
3.2. Albuterol 
Over time, the albuterol-treated group showed similar changes to the control 
group for all respiratory variables at block 4, in comparison to the pre-treatment 
period. However, significant differences were observed at block 3 for TV 
(p=0.0018), MV (p=0.009), peak inspiratory flow (p<0.0001), and peak 
expiratory flow (p=0.005) (Table 1). 
The ANCOVA revealed an increase in TV at T5 (p=0.0106), and a decrease at 
T15 (p=0.001), and T20 min (p=0.011) post-dosing (Fig. 1). MV increased at T5 
(p=0.01) and RR decreased at T25 (p=0.032) and T30 min (p=0.0274) post-
dosing (Fig. 2). Time to peak exploratory flow and IT did not significantly 
change, but ET was increased at T25 (p=0.0354) and T30 (p=0.024). Peak 
inspiratory flow was increased in the albuterol group compared to the saline 
group at T5 (+25%) and T10 (p=0.028). In contrast, peak expiratory flow and 
EF50 were not significantly altered. I:TB ratio significantly decreased at T5 
(p=0.0034), T20 (p=0.0422), T60 (p=0.0071), and T90 (p=0.0287), whilst the 
I:E ratio only reached statistical significance at T60 (p=0.02). Seven out of 8 rats 
presented the same pattern, suggesting that this was a reproducible phenomenon. 
The described changes were marked in 2 rats. 
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3.3. Methacholine 
Over time, the methacholine-treated group presented alterations in all respiratory 
variables, except I:E and I:TB, at blocks 3 and 4 compared to the pre-treatment 
(Table 1).  
The ANCOVA revealed a significant decrease in RR (Fig. 2 and 3) and MV at 
T10, T20, T90, T150, and T180 min post-dosing associated to a compensatory 
increase in TV at T5 and T10 (Fig. 1). Time to peak expiratory flow (+108%, 
p<0.02), IT (+107%, p<0.05), and ET (+39%, p<0.03) were increased at T5 and 
T10, as well as T60, T90, T150, and T180 for ET. Peak inspiratory (+18%, 
p=0.01) and expiratory (+26%, p<0.0001) flows were initially increased at T5. 
Subsequently, peak inspiratory flow decreased at T60 (p=0.028) and T90 (-17%, 
p=0.011) while peak expiratory flow (Fig. 4) and EF50 also decreased at T30, 
T60, T90 (-21% for both), T150 and T180 (p<0.05). I:E ratio was not 
significantly altered, whereas I:TB was reduced at T60 (p=0.0294) and T90 
(p=0.01). In general, the respiratory response to methacholine in rats appeared 
more heterogeneous. A comparable respiratory pattern was observed in 5 out of 
8 rats, and particularly the intensity of the response induced by methacholine 
was high in 3, moderate in 2, and variable in the remaining rats. 
3.4. Remifentanil 
The remifentanil-treated group showed significant alterations in all respiratory 
parameters, except I:E and I:TB, at blocks 3 (p=0.7835, and p=0.9784, 
respectively) and 4 (p=0.1752, and p=0.0773) compared to the pre-treatment, as 
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well as peak inspiratory flow (p=0.25) and EF50 (p=0.0673) at block 3 (Table 
1).  
The ANCOVA revealed a decrease (-13%, p=0.04) in RR (Fig. 2) associated to a 
compensatory increase (+11%, p=0.03) in TV at T5 (Fig. 1). Time to peak 
expiratory flow (+44%, p=0.0002), IT (+35%, p=0.004), and ET (+61%, 
p<0.0001) were increased at T5. Peak expiratory flow was not modified, while 
EF50 was significantly (-11%, p=0.02) reduced at T5 and peak inspiratory flow 
decreased at T10 (p=0.0165) and T15 (-36%, p=0.0008). The I:E ratio was not 
significantly altered, but I:TB was reduced at T10 (p=0.0003), T20 (p=0.0361), 
and T25 (p=0.013). Six out of 8 rats presented the same respiratory pattern, 
suggesting that this was a reproducible phenomenon. 
 
4. Discussion 
As previously reported with this monitoring modality (Hoymann, 2007; Murphy 
et al., 1998), animals appeared calm and relaxed, as indicated by constant and 
normal respiratory parameters over the first 4-hour period of follow-up. Results 
obtained in the control group (saline) suggest that head-out plethysmographs 
resulted in minimal stress to the animals, whereas no respiratory effects were 
observed during the 60-min baseline and the first 2-hour (block 3) post-
treatment. Transient handling-induced perturbations were initially noted after 
placement in the head-out plethysmograph. Our results differ from the 60 to 90 
min perturbations observed after intraperitoneal methylcellulose vehicle 
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administration observed by Delaunois et al. (2009). Result differences may be 
attributed to variation of monitoring environment or handling.  
However, during block 4, animals demonstrated a decrease in RR associated to a 
compensatory increase in TV, but insufficient to avoid a decrease in MV (MV = 
RR * TV). The increases in IT, ET, and time to peak expiratory flow reflect the 
prolongation of inspiratory and expiratory phases and the corresponding RR 
decrease. Flow measurement was less sensitive to detect such change in 
ventilation, as only peak inspiratory flow presented a significant decrease in this 
period. Finally, both ratios were minimally affected by the increased depth in 
tidal ventilation and associated reduction in RR. Such effects could be related to 
a possible slumbering of the rats, occurring after a period exceeding 4 hours 
(most significant results noted at T210 min post-dosing) in the plethysmograph. 
Our results reveal modest but significant variations of respiratory parameters 
over time in saline treated animals, which justify systematic inclusion of a 
control group for inter-group comparison in respiratory safety pharmacology 
studies. Multiple statistical analysis strategies are acceptable in the presence of 
an occasion effect and the ANCOVA with baseline as covariate is considered as 
an appropriate statistical plan to detect the potential respiratory changes induced 
by test articles (Vickers, 2001). The respiratory variables typically included in 
the safety pharmacology core battery (RR, TV, and MV) confirmed their 
sensitivity to detect slight changes related to rat slumbering. Measurements of 
time components are complementary to the change in RR, and flow 
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measurements appeared less sensitive to detect respiratory changes. Finally, I:E 
and I:TB ratios were minimally altered, which suggested limited sensitivity.  
  
Trend graphs on Fig. 1 and 2 illustrate the interrelation between TV and RR 
changes after administration of positive drugs. Albuterol, a ß2-agonist, promotes 
airway relaxation causing predominantly effects on bronchial smooth muscle 
(Ameredes and Calhoun, 2009). In humans, albuterol is administered by 
inhalation and produces a bronchodilation (Pesola and Coelho D’Costa, 2004), 
leading to an increase in TV and MV (Sorbini et al., 1984). Similar responses 
were obtained when tested in dogs and monkeys (Authier et al., 2009). The 
effect has a rapid onset, which is typical for this route of administration with a 
short duration (Dhand et al., 1999). As observed in other species, albuterol 
resulted in a significant increase in TV. The repercussions on MV were only 
present at one time-point (T5), and peak inspiratory flow was increased at T5 
and T10. Consequently, I:TB was reduced, as we had hypothesized that the 
increase in flow rate could lead to a diminution of the inspiratory phase, hence 
the effect on I:TB, even if IT was not sensitive enough to detect this change. 
These results suggest that albuterol-mediated bronchodilation, and subsequent 
decrease in airways resistance are mainly detected by changes in TV and peak 
inspiratory flow.  
Methacholine chloride (acetyl-β-methylcholine) stimulates muscarinic 
postganglionic parasympathetic receptors, causing bronchial smooth muscle 
constriction (Birnbaum and Barreiro, 2007). Intravenous methacholine acts 
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mainly on the airway producing an increase in airway resistance whereas inhaled 
methacholine alters the mechanical properties of both the airways and the lung 
tissues (Petàk et al., 1997). In rats, the bronchial response to a high dose of 
methacholine was characterized with a transient increase in TV associated with a 
persisting decrease in RR and MV. Concurrently, IT, ET, and time to peak 
expiratory flow were all increased, with longer effects for ET. Of all three tested 
positive drugs in this study, methacholine IV injection induced the most 
important respiratory effects. Fig. 3 and 4 illustrate individual variability of RR 
and peak expiratory flow in response to methacholine. Methacholine-induced 
bronchoconstriction is mild in humans (Fujimori et al., 1996) and monkeys 
(Authier et al., 2009) leading to decreased TV and MV. The respiratory response 
to methacholine-induced bronchoconstriction was different in rats (increased 
TV, decreased RR and MV). Despite opposite changes in TV and MV, the 
decrease in peak inspiratory flow, and most importantly in peak expiratory flow 
and EF50 support an increase in airways resistance. Recently, the validity of 
EF50 as a non-invasive measurement of bronchoconstriction in rats was 
questioned (Ewart and Valentin, 2009). Although, EF50 was reduced after 
bronchoconstriction with methacholine in our model, it was also decreased after 
remifentanil which induces a central respiratory depression without recognized 
effects on bronchoconstriction. Interestingly, EF50 was decreased after 
bronchoconstriction (statistically significant) and bronchodilation (not 
statistically significant). A decrease in EF50 should not be systematically 
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attributed to bronchoconstriction and direct measures of pulmonary resistance 
should be considered. 
Remifentanil is an ultrashort-acting and potent μ-opioid leading to central 
respiratory depression (Ansermino et al., 2005). Remifentanil is unique among 
currently available opioids because its ester structure renders it susceptible to 
hydrolysis by non-specific blood and tissue esterases (Feldman et al., 1991). In 
consequence, the decreased firing from respiratory centers leads to 
hypoventilation, characterized by a drop in RR, potentially reaching apnea in 
case of overdose. In the current rat study, we observed similar transient and 
acute bradypnea associated with a compensatory increase in TV, which was even 
more evident with a data analysis at 1-min intervals (Authier et al., 2009). 
Concurrently, IT, ET, and time to expiratory flow increased considerably at T5. 
Peak inspiratory flow and EF50 were transiently reduced at the same time-
points, further supporting the severity of the hypoventilation. 
The three basic respiratory variables (RR, TV, MV) were altered by all 
treatments, either a bronchodilator (albuterol), a bronchoconstrictor 
(methacholine) or a central respiratory depressor (remifentanil). The time-
derived variables were almost systematically and inversely related to the changes 
observed on RR. The flow derived parameters detected changes in ventilation, 
indicative of a certain level of specificity, but these parameters also demonstrate 
the limitations of the model which does not include a direct measure of aurway 
resistance. Globally it would be very difficult to distinguish different levels of 
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bronchodilatation , or even a bronchoconstriction from a bronchodilation. It 
remains that core battery respiratory safety pharmacology is aimed to identify 
possible respiratory liabilities that could later be investigated with follow-up 
studies.  
 
These results confirm the suitability of head-out plethysmography in rats for 
respiratory safety pharmacology as previously reported by Hoymann (2006). In 
addition, data obtained following negative control (saline) suggested a limit of 3 
to 4 hours before slumbering alters respiratory patterns in conscious rats. 
Variations over time in the control group justify the systematic use of a control 
group in any respiratory safety pharmacology study for inter-groups comparison. 
Moreover, the system was sensitive and specific to detect changes in respiratory 
parameters related to pharmacologically-induced bronchodilation (albuterol), 
bronchoconstriction (methacholine) and central respiratory depression 
(remifentanil). In the case of ultrashort-acting agents, such as remifentanil, the 
analysis sensitivity could be improved by shortening the epoch of data analysis 
(analysis on 1 min averages instead of 5 min averages). The three parameters 
(RR, TV, and MV) outlined in the ICH S7A guideline confirmed to be the 
cornerstone of respiratory safety pharmacology data interpretation providing the 
most sensitive detection of changes. The addition of within-breath time 
parameters was not essential to detect drug effects but offered complementary 
tools to interpret changes in RR. Evaluated ratios did not prove to be particularly 
useful in the interpretation of pharmacological respiratory effects in the current 
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study. Nevertheless, evaluation of peak inspiratory / expiratory flow and EF50 
appears as a valuable complement for interpretation of respiratory response, as 
previously suggested (Hoymann, 2007). Peak inspiratory flow was altered by the 
three positive control drug challenges, and peak expiratory flow and EF50 were 
particularly altered by the increase in airways resistance. 
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Table 1 
Effect of positive and negative control substances on some respiratory 
parameters [mean (SD)] in conscious male Sprague–Dawley rats. 
Test  
Substances 
Respiratory rate 
(b/min) 
Tidal volume 
(mL/b) 
Minute volume 
(mL/min) 
Inspiratory 
time 
(sec) 
Mid-tidal 
expiratory flow 
(mL/sec) 
Saline 
Pre-Rx 200.16 (27.43) 1.39 (0.11) 264.46 (28.85) 0.20 (0.03) -12.33 (1.27) 
Post-Rx 0-2 h 198.49 (38.66) 1.40 (0.11) 261.18 (48.93) 0.21 (0.06) -12.46 (1.64) 
Post-Rx 2-4 h 182.54 (38.44)* 1.44 (0.14)* 249.86 (53.91)* 0.24 (0.06)* -12.45 (1.27) 
Albuterol 
Pre-Rx 171.81 (37.05) 1.62 (0.11) 273.11 (60.08) 0.22 (0.06) -11.33 (2.57) 
Post-Rx 0-2 h 162.15 (34.39) 1.65 (0.17)* 255.15 (57.02)*, 0.23 (0.03) -11.04 (2.46) 
Post-Rx 2-4 h 157.94 (31.45)* 1.66 (0.11)*, 250.22 (39,60)* 0.24 (0.03)* -11.38 (2.69) 
Methacholine 
Pre-Rx 208.06 (39.57) 1.31 (0.08) 263.04 (46.58) 0.19 (0.03) -11.99 (1.78) 
Post-Rx 0-2 h 166.97 (31.59)*, 1.47 (0.25)*, 232.85 (41.83)* 0.24 (0.11)*, -10.72 (1.75)*,
Post-Rx 2-4 h 161.73 (44.29)*, 1.48 (0.11)* 228.73 (52.72)*, 0.25 (0.06)* -10.59 (2.77)*,
Remifentanil 
Pre-Rx 188.70 (31.31) 1.52 (0.17) 271.62 (56.51) 0.20 (0.03) -11.94 (1.95) 
Post-Rx 0-2 h 170.27 (39.88)*, 1.61 (0.14)*, 260.90 (51.79)* 0.23 (0.06)*, -11.50 (2.72) 
Post-Rx 2-4 h 171.37 (35.38)* 1.59 (0.20)* 257.04 (45.59)* 0.23 (0.03)* -11.69 (2.63) 
 
*Intragroup significant difference (within-time evaluation by post-dosing blocks comparison to pre-treatment period) 
Intergroup significant difference (ANCOVA comparison to the placebo-controlled group via Dunnett’s test at each 
significant time-point) 
 
 
 
 
 
65 
 
Figure legends 
Photo 1. A-The SCIREQ computerized system; B-A rat in place in the head-out 
plethysmograph. 
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Fig. 1. Tidal volume (TV) evolution in each treated group from baseline to 60-
minute post-dosing. Histogram is presenting group mean ± SEM at each selected 
time-point, whereas the trend curve is a mobile average (period of 2). 
Saline (2.0 mL/kg IV); Albuterol (400 μg/kg inhalation); Methacholine (136 
μg/kg, 2.0 mL/kg IV); Remifentanil (14 μg/kg, 2.0 mL/kg IV). ANCOVA with 
baseline score as a covariate, comparing saline to positive drugs, was performed 
to detect intergroup difference, with a posteriori pair-wise comparisons using 
Dunnett’s test (* = p < 0.05). 
Trend curve clearly highlights the significant within-time change in TV after 
saline injection at T5. Compared to the saline control group, albuterol inhalation 
increased significantly TV at T5, and decreased it at T15 and T20. Methacholine 
induced a significant increase at T5 and T10. Remifentanil increased 
significantly at T5. 
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Fig. 2. Respiratory rate (RR) evolution in each treated group from baseline to 
60-minute post-dosing. Histogram is presenting group mean ± SEM at each 
selected time-point, whereas the trend curve is a mobile average (period of 2). 
Saline (2.0 mL/kg IV); Albuterol (400 μg/kg inhalation); Methacholine (136 
μg/kg, 2.0 mL/kg IV); Remifentanil (14 μg/kg, 2.0 mL/kg IV). ANCOVA with 
baseline score as a covariate, comparing saline to positive drugs, was performed 
to detect intergroup difference, with a posteriori pair-wise comparisons using 
Dunnett’s test (* = p < 0.05). 
Trend curve shows the within-time stability of RR in the saline control group. 
Albuterol induced an initial increase in RR (which was not statistically 
significant) followed by a significant decrease at T25 and T30. Methacholine 
induced a significant (at T10 and T20) and persisting decrease in RR. 
Remifentanil induced a transient decrease in RR, significant only at T5. 
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Fig. 3. Individual changes (n=8) observed in respiratory rate (RR) of rats 
following administration of methacholine (136 μg/kg, 2.0 mL/kg IV). 
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Fig. 4. Individual changes (n=8) observed in peak expiratory flow (PEF) of rats 
following administration of methacholine (136 μg/kg, 2.0 mL/kg IV). The values 
are indicated as negative, but the changes were described on the absolute values 
(i.e. what was described as a decrease in PEF was for example the change from -
15 to -10 mL/sec). 
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SECOND ARTICLE: 
 
RESPIRATORY SAFETY PHARMACOLOGY: POSITIVE CONTROL 
DRUG RESPONSES IN SPRAGUE-DAWLEY RATS, BEAGLE DOGS 
AND CYNOMOLGUS MONKEYS. 
 
This manuscript has been published in the Journal of Regulatory Toxicology and 
Pharmacology. The aim of this study was to compare the respiratory changes 
induced by drugs with pharmacologically-known effects, on 40 conscious 
Sprague Dawley male rats, 18 Beagle dogs (6 males and 12 females), as well as 
8 Cynomolgus monkeys (4 males and 4 females).  
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ABSTRACT 
Rats are most frequently used to fulfill ICH S7A requirements for respiratory 
safety pharmacology. We hypothesized that the models used to assess respiratory 
safety pharmacology present different ventilatory responses to 
bronchoconstriction, bronchodilation and respiratory depression. Respiratory 
monitoring was performed with head-out plethysmographs for rats, masks for 
dogs and bias airflow helmets for monkeys. Respiratory rate (RR), tidal volume 
(TV) and minute volume (MV) were recorded. Forty rats, 18 dogs and 8 
monkeys were acclimated to the respiratory monitoring equipment. Animals 
received saline (IV), albuterol (inhalation), methacholine (IV) and remifentanil 
(IV). Albuterol increased TV in all species.  Methacholine decreased TV and 
MV in monkeys. In dogs, methacholine increased TV, RR and MV. In rats, 
methacholine increased TV and decreased RR. Remifentanil induced central 
respiratory depression in all species with decreased MV, except in rats. Dogs 
presented a biphasic response to remifentanil with hypoventilation followed by 
delayed hyperventilation. The monkeys presented similar responses to humans 
which may be due to biologic similarities. Dogs and rats presented clinically 
significant ventilatory alterations following positive control drugs. Although, the 
response to bronchoconstriction in dogs and rats was different from humans, the 
two species presented ventilatory changes that highlight the potential adverse 
effect of test articles.  
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1. INTRODUCTION 
The ICH S7A Guideline defines the safety pharmacology core battery 
including cardiovascular (CVS), central nervous system (CNS) and respiratory 
(U.S. Food and Drug Administration, 2001). The guideline states that 
“respiratory rate and other measures of respiratory function (e.g. tidal volume 
or hemoglobin oxygen saturation) should be evaluated”. A recent industry 
survey revealed that respiratory rate, tidal volume and minute volume are 
included in 98 to 100% of core battery and supplemental respiratory safety 
pharmacology studies (Lindgren et al. 2008). Study design in safety 
pharmacology is constantly evolving prodded by emerging technologies 
(Hoymann, 2007; Murphy et al., 1998; Murphy et al., 2001) and integrated drug 
development where in vitro, preclinical and clinical safety testings share a 
common goal, drug approval. Sensitivity of the model should be commensurate 
with the risk in our drug development industry where resources are scarce and 
time is felt by drug companies with aging drug patents. Blood gases, reported to 
have limited sensitivity (due to complex compensatory mechanisms) to detect 
drug-induced adverse effects (Authier et al., 2008), and RR are occasionally 
used as sole in-vivo markers of preclinical respiratory safety. With the addition 
of histopathological assessments, these two in-vivo biomarkers (blood gases and 
RR) are, in some cases, considered acceptable for respiratory safety testing (e.g. 
some oncology indications).  
When non-clinical and clinical reasons for drug development 
discontinuation are combined, respiratory adverse effects are less frequent than 
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CVS or CNS (Valentin & Hammond, 2008). Moreover, respiratory safety 
pharmacology is less frequently frontloaded (performed earlier in the drug 
development process) than CVS and CNS which may suggest a perceived lower 
risk of respiratory liability in comparison to the other two systems included in the 
safety pharmacology core battery.  
The rat is used as the preferred species for respiratory safety in most 
investigational new drug (IND) programs (Lindgren et al. 2008). Advantages to 
the use of rats are numerous including high genetic homogeneity which reduces 
variability, lower test material requirements, abundant historical data and ethical 
considerations which favour the use of a phylogenically lower laboratory animal 
species. On the flip side, the use of rats may present disadvantages including 
limited genetic diversity which may not be representative of the human patient 
population. Respiratory anatomy, physiology and pathology in rats are relatively 
different from humans, an adaptive response to their respective normal habitat. 
Large laboratory animals such as dogs and monkeys present respiratory system 
characteristics which could be considered closer to humans.  
IND submissions often require that a small and a large animal species be 
selected for toxicology studies. CVS safety pharmacology assessments are most 
frequently performed in large animals (Lindgren et al., 2008) using dogs (Gauvin 
et al., 2006) or monkeys (Authier et al., 2007). Respiratory assessments to fulfil 
S7A can be performed using minimally invasive methodologies in toxicology 
studies or in large animals used for CVS safety pharmacology without the need 
to use additional animals. As large animals present biologic similarities with 
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human patients, inclusion of respiratory measures in large animal studies may 
increase the clinical relevance of these investigations. The current project 
presents the ventilatory responses of common respiratory safety pharmacology 
models to bronchodilation, bronchoconstriction and respiratory depression using 
well characterized pharmaceutical agents.  
2. MATERIALS AND METHODS 
2.1. Statement on use and care of animals and regulatory compliance. During 
the study, care and use of animals were conducted in accordance with principles 
outlined in the current Guide to the Care and Use of Experimental Animals 
published by the Canadian Council on Animal Care and the Guide for the Care 
and Use of Laboratory Animals published by the U.S. National Institutes of 
Health (NIH Publication No. 85-23, revised 1996). LAB Research Inc.’s facility 
is AAALAC accredited. Data were obtained under studies conducted in 
accordance with the Good Laboratory Practice (GLP) regulations of the United 
States Food and Drug Administration (21 CFR Part 58 and subsequent 
amendments). 
2.2. Animal housing and preparation. The experimental population comprised 
forty (40) male Sprague-Dawley rats (242 to 315g, 59 to 65 days), eighteen (18) 
Beagle dogs (6 males and 12 females, 8 to 18 kg, 1 to 4 yrs) and eight (8) 
cynomolgus (Macaca fascicularis) monkeys (4 males and 4 females, 2.5 to 4.6 
kg, 3 to 5 yrs old). The animal room environment was controlled and monitored 
continuously (targeted ranges: temperature 21 ± 3°C, humidity 30-70%, 12 hours 
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light, 12 hours dark, 10-15 air changes per hour). Rats were fed a standard rodent 
chow ad libitum (Teklad Certified 18% Rodent Diet #2018C). Dogs received a 
standard certified commercial dog chow (400 g of Harlan Teklad Certified 25% 
Lab Dog Diet #8727C) over a 24-hour feeding period. A standard certified 
commercial primate chow (Teklad Certified Global 25% Primate Diet # 2055C) 
was made available to each monkey twice daily. Clinical signs were evaluated at 
cage side at least once daily, and a detailed clinical examination was performed 
at transfer and once weekly throughout the studies. 
2.3. Respiratory Monitoring System. Respiratory rate (RR), tidal volume (TV) 
and minute volume (MV) were recorded continuously at a sampling frequency of 
200 Hz in all species. Respiratory function was monitored in rats using head-out 
plethysmographs (Model PC-H2, SCIREQ Inc., Montreal, QC, Canada) with 
opaque headrest connected to a pneumotachometer (Model 8420 with a 5 L/min 
capacity, HANS RUDOLPH, MO, U.S.A.). The headrests were such that the 
nose of the rats was open to ambient air but visual and auditory stimulations 
were attenuated providing a more comfortable environment for the animals. 
Airflow signals from rat pneumotachometers were monitored using precision 
differential pressure transducers (Model UT-PDP-02, 0.2 kPa nominal, SCIREQ 
Inc., Montreal, QC, Canada) connected to the data acquisition matrix (In expose-
08, Data Acquisition Controller 8 channels, SCIREQ Inc., Montreal, QC, 
Canada) and a real-time respiratory analyzer (flexiWare 5.3.1, SCIREQ Inc., 
Montreal, QC, Canada).  
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Respiratory monitoring was performed in conscious Beagle dogs as 
previously described (Authier et al., 2008). In brief, canine respiratory function 
was monitored using a computerized system composed of a data acquisition 
controller (DAC 8, Scientific Respiratory Equipment Quebec Inc. (SCIREQ), 
Montreal, QC, Canada) using a real-time respiratory analyzer (flexiWare 5.1, 
SCIREQ Inc., Montreal, QC, Canada) connected to pneumotachometer (Model 
3719 with a 100L/min capacity, HANS RUDOLPH, MO, U.S.A.) with 
individual heater controllers (HANS RUDOLPH, MO, U.S.A.) connected to a 
face mask.  
Respiratory function was monitored in conscious cynomolgus monkeys 
using a computerized system composed of a data acquisition controller (In 
expose-08, Scientific Respiratory Equipment Quebec Inc. (SCIREQ), Montreal, 
QC, Canada) connected to a computer (OptiPlex GX280 Workstation, DELL, 
Dallas, TX, U.S.A.) with a real-time respiratory analyzer (flexiWare 5.1, 
SCIREQ Inc., Montreal, QC, Canada). The respiratory hardware included 
pneumotachometer (Model 3500 with a 35L/min capacity, HANS RUDOLPH, 
MO, U.S.A.) with individual heater controller (HANS RUDOLPH, MO, 
U.S.A.). Monkeys were acclimated to a restraining chair and a transparent 
plexiglass helmet (LOMIR BIOMEDICAL, Notre-Dame-de-l’Île-Perrot, QC, 
Canada) with a biais airflow (inExpose pump module 2.5 lpm, SCIREQ Inc., 
Montreal, QC, Canada) and continuous helmet pressure monitoring (Model UT-
PDP-25, 2.5 kPa nominal, SCIREQ Inc., Montreal, QC, Canada). Helmet 
pressure was maintained neutral to ambient pressure.    
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Rats, dogs and monkeys were acclimated to respiratory monitoring on three (3) 
different occasions before initiation of treatment. Rats and dogs that did not 
tolerate the respiratory monitoring were replaced by animals kept in the same 
experimental conditions. Respiratory monitoring was well tolerated by all 
monkeys assigned to the study and no replacement was required.  
2.4. Positive and negative control drugs. Saline (BAXTER, ON, Canada), 
albuterol (RATIOPHARM Inc, QC, Canada), methacholine (SIGMA-
ALDRICH, ON, Canada) and remifentanil (Ultiva®, ABBOTT 
LABORATORIES Ltd., ON, Canada) were administered to conscious rats, dogs 
and monkeys at doses selected based on historical data obtained in previous 
studies conducted at LAB Research and adjusted for body surface area (BSA) to 
induce slight and moderate to severe respiratory effects as presented in Table 1. 
The dose volume was 2.0 mL/kg for rats, and 0.2 mL/kg for dogs and monkeys 
(all intravenous agents). Albuterol was administered using a pressurized 
metered-dose inhaler with a holding chamber and a mask. Monitoring was 
initiated at least 15 min before dosing in all species. Respiratory data during the 
first 20 min after administration was used for comparison between species given 
the rapid onset of pharmacological effects with selected agents.  
2.5. Data analysis. Data were averaged every 5 min and results following 
positive control drugs compared with saline administration. For rats, one (1) min 
averages at peak effect were also calculated. Normality of distribution was 
evaluated using the Shapiro-Wilk test. The Levene test was used to examine the 
homogeneity of group variances. When both of these tests were found to be non-
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significant, analysis of variance (ANOVA) was considered appropriate. 
Whenever the overall group differences were shown significant (F-Test for 
ANOVA), then pair-wise comparisons were conducted using Dunnett’s test for 
ANOVA. Comparisons among dose levels at each timepoint were done using a 
T-test and including the Satthertwaite method in presence of heterogenous group 
variances. Results are presented as mean values ± standard error of the mean 
(SEM).  
3. RESULTS 
Average RR after saline treatment was 175 ± 15 b/min, 16.4 ± 3.3 b/min and 
50.5± 3.7 b/min in rats, dogs and monkeys, respectively. Average TV after saline 
treatment was 1.30 ± 0.07 mL, 217 ± 75 mL and 42 ± 17 mL in rats, dogs and 
monkeys, respectively. Mean MV following saline administration were 0.257 ± 
0.004 L/min, 4.050 ± 0.407 L/min and 2.054 ± 0.315 L/min in rats, dogs and 
monkeys, respectively.  
Albuterol administered by inhalation induced an increase in TV (Fig. 1) 
in rats, dogs and monkeys when using an analysis with 5 min averages for a 20 
min monitoring period compared with saline treatment. Changes to RR were not 
statistically significant (Fig. 2) in any species during the 20 min monitoring 
period following treatment, while MV was significantly increased in dogs and 
monkeys (Fig. 3). 
Monkeys presented a decrease in TV (p<0.01) and MV (p<0.01) 
following administration of methacholine with a trend to a compensatory 
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increase in RR at higher doses (Fig. 4). In contrast, respiratory monitoring in 
dogs differed with the dose of methacholine: at low dose (2 µg/kg), only MV 
presented a statistically significant change associated with a decrease in TV and 
an increase in RR at T10 min; at high dose (8 µg/kg) dogs presented an initial 
increase in RR (p<0.01) followed by an increase in TV (p<0.05) associated to a 
decrease in RR and a sustained increase in MV (p<0.05) (Fig. 5). In rats, 
systemic administration of methacholine resulted in dose-dependent effects: at 
low dose (28 µg/kg), no statistically significant effect was observed (Fig. 6), but 
at high dose (136 µg/kg), methacholine induced a significant increase in TV 
(p<0.01) with a decrease in RR (p<0.05) (Fig. 6).  
As expected for a potent mu agonist opioid, remifentanil induced a 
significant respiratory depression in all three species (Table 2). Rats presented an 
initial and transient (at T5) decrease in RR, immediately compensated by a 
transient (at T10 and T15) increase in TV, without significant change in MV. 
When using one (1) min averages starting at pharmacological onset, RR (-37.4% 
± 4.2%) and MV (-32.6% ± 5.3%) were significantly decreased (p<0.01) in rats 
following 14 μg/kg remifentanil administration. Dogs presented a biphasic 
response with hypoventilation followed by a delayed phase of hyperventilation 
with increased RR. Panting was noted in some dogs when adverse respiratory 
effects were seen which complicated respiratory analysis with this species. In 
monkeys, apnea was observed in 3 out of 7 monkeys at high dose (6.4 μg/kg), 
which prompted reversal of the opioid effects with naloxone (0.4 mg/mL, IV). 
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4. DISCUSSION 
Species differences are recognized by regulators and dictate selection of 
maximum safe starting dose during initial clinical trials in healthy volunteers 
(U.S. Food and Drug Administration, 2005). Allometric correlations have been 
reported between species for metabolic rates but also for physiological 
parameters such as heart rate (West et al., 2002), cardiac output, respiratory rate 
and ventilation (Lindstedt & Schaeffer, 2002). Allometric correlation between 
body weight and MV has been recognized for several decades (Guyton, 1947; 
Stahl, 1967). Inter-species correlations are recognized de facto in toxicology 
which uses models from multiples species to predict the human response. 
Allometric scaling of respiratory parameters is also a central exercise in 
inhalation toxicology studies for dose estimation. A formula (V(m)=0.608 
BW0.852) to estimate respiratory MV adapted to laboratory animals (mouse, rat, 
dog and monkey) was recently published by the Association of Inhalation 
Toxicologists (AIT) (Alexander et al., 2008). When using the recent AIT 
formula, the predicted MV (rats 0.191 ± 0.003 L/min; dogs 5.227 ± 0.225 L/min; 
monkeys 1.759 ± 0.100 L/min) were closer to actual respiratory measurements 
following saline administration than the predicted MV calculated (rats 0.166 ± 
0.002 L/min; dogs 3.846 ± 0.196 L/min; monkeys 1.368 ± 0.074 L/min) with the 
Bide formula (V(m)=0.499 BW0.809) which is commonly used for dose 
calculation in inhalation toxicology studies (Bide et al., 2000). These results 
support the superior predictive value of the recent AIT formula to estimate MV 
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when compared with the Bide formula. This closer correlation between predicted 
and measured MV using the AIT formula supports the use of the later in our 
experimental conditions. The importance to evaluate standard formulas with in-
house data was demonstrated for QT correction formulas (Tattersall et al., 2006). 
Similarly, allometric formulas used in dose calculation for inhalation toxicology 
studies benefit from qualification using actual MV values recorded in 
experimental conditions that prevail in each laboratory.    
In humans, systemic administration of albuterol induces a significant 
increase in TV and MV (Sorbini et al., 1984) which is thought to result from an 
increased metabolic rate and serum lactate (Tobin et al., 2006). Similar to 
humans, monkeys and dogs presented a significant increase in TV and MV, 
while only increase in TV reached statistical significance in rats when compared 
with Saline. The duration of effects was longer in monkeys when compared to 
dogs at equivalent doses (0.1 mg/kg in dogs and 0.2 mg/kg in monkeys). This 
could be related to a greater respiratory reserve in dogs which resulted in a rapid 
compensation. Albuterol by inhalation induces tachycardia with a decrease in 
systolic pressure in beagle dogs (Petruska et al., 1997). Similarly, rats presented 
tachycardia following inhaled albuterol at doses of 84 μg/kg (4.8 times lower 
than the dose used in the current study). Doses up to 7.5 times higher than the 
high dose (0.2 mg/kg) used in this study did not produce significant 
cardiovascular effects in cynomolgus monkeys. Cardiovascular effects of 
albuterol, also reported in healthy volunteers (Corea et al., 1984), may contribute 
to respiratory changes when using this positive control drug in respiratory safety 
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models and in humans. Differences in ventilatory responses observed between 
the three models may be due to species specific sensitivity to cardiovascular 
and/or respiratory effects. Cardiopulmonary dependency is an emerging concept 
in safety pharmacology that often requires monitoring of the respiratory and 
cardiovascular systems simultaneously in the same animals to identify 
correlation between the two systems. 
Methacholine at the high dose (8 μg/kg in dogs and 13.5 μg/kg in 
monkeys) induced diametrically opposite effects with a significant increase of 
MV in dogs while monkeys presented a decreased MV. Whereas TV was 
consistently decreased in monkeys at high dose methacholine, in dogs, TV was 
initially slightly reduced as previously reported (Savoy et al., 1982) and 
associated with an abrupt increase in RR, followed by a second phase of 
respiratory response including increase in TV and return toward baseline values 
for RR. Such results suggest that the dog is highly responsive to the 
bronchoconstrictive effects of methacholine resulting in an abrupt increase in 
RR. Healthy humans are reported to present a decreased MV and TV (Fujimori 
K et al., 1996) similar to the response observed in monkeys. Similar to dogs, the 
rats presented a response different from humans and monkeys with an increase 
in TV and a decrease in RR at the doses used in the current study.  It remains 
that all three (3) species presented significant ventilatory changes following 
bronchoconstriction with methacholine and are considered suitable models to 
detect the presence of respiratory liability. Core battery safety pharmacology 
studies should identify potential adverse effects in human patients. The response 
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to bronchoconstriction, although different between species, will yield the same 
conclusion; identification of a potential respiratory (adverse) effect in humans 
which will trigger appropriate monitoring during early clinical trials. 
Remifentanil, a potent mu-agonist opioid, leads to respiratory depression 
in humans (Smith et al., 1997), which translates into decreased MV. Expected 
effects were observed in all species, but in rats the depression was more evident 
with the analysis at one (1) minute interval. Indeed for rats, analysis at onset of 
pharmacological effects with one (1) min averages revealed higher sensitivity to 
detect changes after remifentanil administration. The difference in statistical 
results between one (1) and five (5) min averages highlights the importance of 
post-acquisition data analysis which needs to be tailored to each test article in 
order to capture pharmacological effects. On the other hand, adapting statistical 
analysis at posteriori to capture an unknown pharmacodynamic response is a 
challenging issue in regulatory toxicology where any modification to the 
analysis plan would raise concerns on potential bias.  
Results from the current study suggest that the ventilatory response to 
bronchoconstriction in the monkey is closer to humans. These pharmacodynamic 
similarities correlate with anatomic, physiologic and histologic characteristics of 
monkeys that resemble humans while dogs and rats present lower level of 
homology with humans. Monkeys (Dungworth et al., 1975), dogs (Takenaka et 
al., 1998) and humans (Saetta et al., 1994) have several generations of 
respiratory bronchioles while rats have either no respiratory bronchioles of a 
single generation (Tyler & Julian, 1991; Saetta et al., 1994). The number of 
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alveolar pores, which facilitates collateral ventilation, is similar in dog, monkey 
and human alveolus but lower in rats (Port et al., 1977). Submucosal glands are 
observed throughout the bronchial tree of dog (Takenaka et al., 1996), monkeys 
(El-Bermani & Grant, 1975) and humans (Scott, 1973) while rats do not have 
bronchial glands (Jeffery, 1983).  Respiratory neural organization in monkeys, 
dogs and rats is comparable to humans (Kastner & Gauthier, 2008) with 
respiratory centers (inspiratory, expiratory, pneumotaxic and apneustic) located 
in the medulla oblongata and multiple nervous effectors controlling ventilation 
such as the phrenic and intercostal nerves (King, 2005). Despite central 
similarities the pulmonary innervation presents differences between species. The 
rat lung innervation presents significant differences when compared with 
monkeys (El-Bermani, 1978) while lung innervation in dogs is comparable to 
monkeys (Knight et al., 1981). Will anatomical and physiological similarities 
between monkeys and humans translate into increased predictive value with this 
species? If so, will increased predictive value alter the decision making process 
during drug development? The answer resides in an integrated risk assessment of 
the toxicology testing plan. Despite differences between humans and rats, the rat 
model is widely accepted in pharmaceutical research (Tschernig et al., 2008) and 
this species remains predictive of the patient response. Clinically significant 
alterations to respiratory parameters were noted in rats with all positive control 
drugs used in this study supporting the use of the three species for respiratory 
safety investigations.  
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The current study holds some limitations and complete dose-response 
curves would be needed to compare species sensitivity. It remains that dose 
levels that were used reliably induce bronchoconstriction, bronchodilation and 
respiratory depression given the well-characterized positive control drugs that 
were selected. As observed in the current study, dogs occasionally present 
panting when stressed or in response to drug induced adverse effects. Panting 
during respiratory monitoring acclimation in dogs triggers exclusion of 
individuals. When present, panting decreases accuracy of the ventilatory 
measures and increases artefacts due to excessively rapid ventilation of the 
respiratory dead space. Occasional panting is an inconvenient of the canine 
model and the rat can be preferred for respiratory safety testing when these two 
species are selected for toxicology studies. In contrast, the cynomolgus monkey 
maintains a tidal breathing pattern and the inclusion of non-invasive respiratory 
(ventilatory) investigations in toxicology studies may present some advantages 
over ventilatory assessments in rats.  
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Table 1 
Dose levels of positive control drugs       
  Route Rats Dogs Monkeys 
Saline IV -- -- -- 
Albuterol  (μg/kg) Inhalation 400 100 100 
        200 
Methacholine  (μg/kg) IV 28 2 3.4 
  136 8 13.5 
        68.0 
Remifentanil (μg/kg) IV 14 4 3.4 
        6.8 
 
 
Table 2 – Respiratory parameters following remifentanil (5 min averages starting 
at injection) 
    Dose 
Respiratory Rate 
(b/min) 
Tidal Volume 
(mL) 
Minute Volume 
(mL/min) 
         
Control 
Articles   μg/kg Pre-Rx Post-Rx Pre-Rx Post-Rx Pre-Rx Post-Rx 
         
Sprague-
Dawley Rats  
(n=8) 14 188.7  
± 10.4 
164.4* 
± 7.3  
1.517  
± 0.069 
1.683* 
± 0.089 
271.6  
± 13.5 
262.4  
± 12.0 
Beagle Dogs 
(n=7) 4 15.8  
± 2.3 
11.6*  
± 0.8  
270.7  
± 19.4 
243.2  
± 24.3 
3913  
± 440 
2339**  
± 193  
Cynomolgus 
Monkeys  
(n=8) 3.4 49.2  
± 3.2 
39.6  
± 2.5 
39.4  
± 3.5 
23.0** 
± 3.2  
1864  
± 163 
911**  
± 165  
 
(n=7)a 6.8 50.4  
± 4.4 
41.7  
± 3.4  
41.6  
± 3.9 
28.4*  
± 4.5  
1945  
± 143 
1297*  
± 287  
                  
 * p<0.05, **p<0.01 
a Effects of remifentanil was reversed with naloxone IV for 3 out 7 animals due to 
severe apnea. 
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Figures 
  
FIG. 1. Tidal volume (TV) after albuterol administered by inhalation to 
Sprague-Dawley rats (n=8), Beagle dogs (n=5) and cynomolgus monkeys (n=8). 
Overall group difference when compared with saline was significant for rats 
(p<0.05), dogs (p<0.05) and monkeys at 0.2 mg/kg (p<0.01).  
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FIG. 2. Respiratory rate (RR) following albuterol administered by inhalation to 
Sprague-Dawley rats (n=8), beagle dogs (n=5) and cynomolgus monkeys (n=8). 
Overall group difference when compared with saline using ANOVA was not 
significant for any of the 3 species during the 20 min monitoring period with 5 
min averages.   
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FIG. 3. Minute volume (MV) following albuterol administered by inhalation to 
Sprague-Dawley rats (n=8), beagle dogs (n=5) and cynomolgus monkeys (n=8). 
The overall group difference was statistically significant when compared with 
saline for dogs (p<0.01) and monkey at 0.2 mg/kg (p<0.01), while overall group 
difference did not reach statistical significance in rats when compared with 
saline.  
** = p < 0.01.  
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FIG. 4. Respiratory monitoring following methacholine bolus administration 
(IV) to cynomolgus monkeys (n=8). Overall difference was significant for tidal 
volume (p<0.01) and minute volume (p<0.01) and significance at each dose is 
presented above. A trend to compensatory increase in respiratory rate was 
observed following methacholine administration at 13.5 and 68 μg/kg.  
* = p < 0.05, ** = p < 0.01.  
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FIG. 5. Tidal volume (5A), respiratory rate (5B) and minute volume (5C) 
following methacholine bolus administration (IV) to beagle dogs (n=8). The 
overall difference was significant for MV at 2 μg/kg (p<0.01) and for all 3 
parameters at 8 μg/kg (RR, p<0.01; TV, p<0.05; MV, p<0.05). At 8 μg/kg, a 
sustained increase in MV is explained by a biphasic response, with an initial 
increase in RR, followed by an increase in TV while RR is returned toward 
baseline.  
* p<0.05; ** p<0.01 
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
5 10 15 20
Time post-dosing (min)
%
 c
ha
ng
e 
fr
om
 b
as
el
in
e
MV 0.02 mg/kg
MV 0.08 mg/kg
103 
 
 
FIG. 6. Respiratory monitoring (5 min average at pharmacological onset) 
following methacholine bolus administration (IV) to Sprague-Dawley rats (n=8). 
When compared with saline, RR was decreased (p<0.05) and TV was increased 
(p<0.01) after methacholine at 136 μg/kg. The changes in RR (p=0.07) and MV 
(p=0.11) at 28 μg/kg did not reach statistical significance.  
* = p < 0.05, ** = p < 0.01. 
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6. DISCUSSION AND CONCLUSION 
 
The objective of the first study was to evaluate the performance 
qualifications of the FlexiWare® system in conscious Sprague-Dawley male rats 
following the administration of pharmacological substances with known effects 
on the respiratory system.  
In studies using laboratory animals, to obtain reliable results, it is 
important to address the potential effects of exterior factors that may affect the 
response of the animals. Savoy et al. (1982) suggested the use of non-invasive 
methods which are less stressful to animals and do not require anaesthesia, 
analgesia, or sedation. In our study, the respiratory function was monitored using 
head-out plethysmographs. It is a non-invasive procedure requiring no 
anaesthesia, analgesia, nor sedation. It was well tolerated by the animals. Indeed 
the animals appeared calm and relaxed as indicated by constant and normal 
respiratory parameters over the first 4-hour period of follow-up. Results obtained 
in the control group (saline) suggest that head-out plethysmographs resulted in 
minimal stress to the animals, whereas no respiratory effects were observed 
during the 60-min baseline and the first 2- hour (block 3) post-treatment.  
The FlexiWare® system version 5.3.1® used could detect the response of 
the rats following inoculation of the pharmacological substances used. We also 
demonstrated that this system could detect the response of the Beagle dogs and 
Cynomolgus monkeys following administration of the similar substances 
(Authier et al. 2009).  
In the rat model used in this study, as well as in the Beagle dogs and in 
the Cynomologus monkeys, the system responded very well. The three basic 
parameters (RR, TV, and MV) outlined in the ICH S7A guideline confirmed to 
be the cornerstone of respiratory safety pharmacology data interpretation 
providing the most sensitive detection of changes. The system was sensitive and 
specific to detect changes in respiratory parameters related to pharmacologically-
induced bronchodilation (albuterol), bronchoconstriction (methacholine) and 
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central respiratory depression (remifentanil). In the case of ultra-short-acting 
agents, such as remifentanil, the analysis sensitivity could be improved by 
shortening the epoch of data analysis (analysis on 1 min averages instead of 5 
min averages), as particularly demonstrated for rats (Authier et al. 2009). The 
use of a more sensitive statistical method could also help to evaluate the effects 
of the ultra-short-acting agents. The addition of within-breath time parameters 
(IT, ET, and time to peak expiratory flow) was not primordial to detect drug 
effects but offered complementary tools to interpret changes in RR.  
We have also evaluated more flow-derived parameters such as peak 
inspiratory flow, peak expiratory flow, and mid-tidal expiratory flow (EF50), as 
well as ratio-derived variables, e.g. inspiratory:expiratory (I:E) ratio and 
inspiratory to total breath (I:TB) ratio.  Flow-derived variables appeared as 
highly valuable complement for interpretation for respiratory response. The 
ratio-derived parameters did not prove to be particularly useful in the 
interpretation of pharmacological respiratory effects in the current study. 
Nevertheless, evaluation of peak inspiratory / expiratory flows and EF50 appears 
as a valuable complement for interpretation of respiratory response, as 
previously suggested (Hoymann, 2007). Peak inspiratory flow was altered by the 
three positive control drug challenges, and peak expiratory flow and EF50 were 
particularly affected by the increase in airways resistance. 
The three animals species used in this study (rats, Beagle dogs and 
Cynomologus monkeys) adapted well to the apparatus. However each species 
presented some particularities. 
In the rat model, the duration of the testing period seem to be critical. 
Indeed, the animals showed a normal breathing pattern during the first three to 
four hours of testing. However, passed that period, unexpected breathing patterns 
were observed in both control and treated animals. Therefore, this makes 
interpretation of drug-induced effects more complex over this period. 
Furthermore, the data collection method raised a question that needs to be 
addressed. In the case of a drug producing a rapid action of a short duration (e.g., 
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remifentanil), the effect of the drug cannot be detected when block data (average 
data collected during 2 hours post treatment) were compared with block data 
from control animals collected during the same period. 
In the canine model we had observed that there is presence of 
occasionally panting when dogs were stressed or in response to drug-induced 
adverse effects. It is an important inconvenient when present. Panting decreases 
accuracy of the ventilatory measures and increases artefacts due to excessively 
rapid ventilation of the respiratory dead space.  
In contrast, the cynomolgus monkey maintains a tidal breathing pattern 
and the inclusion of non invasive respiratory (ventilatory) investigations in 
toxicology studies may present some advantages.  
Albuterol, considered the most widely used ß2-agonist for asthma, has an 
efficacy, safety and selectivity profile that makes it the drug of choice as rescue 
therapy in acute asthma exacerbations and symptoms. Albuterol promotes 
airway relaxation causing predominantly effects on bronchial smooth muscle 
(Ameredes & Calhoun 2009). In monkeys and dogs an increase in TV and MV 
were observed. However in rats, a significant increase in TV and peak 
inspiratory flow were noted leading to a diminution in inspiratory phase. The 
repercussions in MV were only present at one time point. These results suggest 
that albuterol-mediated bronchodilation, and subsequent decrease in airways 
resistance is mainly detected by changes in TV and peak inspiratory flow.  
Methacholine chloride (acetyl-â-methylcholine) is a 
parasympathomimetic synthetic analog of acetylcholine. It stimulates muscarinic 
postganglionic parasympathetic receptors, causing bronchial smooth muscle 
constriction (Birnbaum & Barreiro 2007). The MV and TV were decreased in 
monkeys as similar effects in humans (Fujimori et al. 1996). In MV, an opposite 
effect was noted in dogs compared to monkeys. In dogs, TV was initially slightly 
reduced and associated with an abrupt increase in RR, followed by a second 
phase of respiratory response including an increase in TV, MV and return toward 
baseline values for RR. These suggest that the dog is highly responsive to the 
107 
 
bronchoconstrictive effects of methacholine. In rats the response was different 
from monkeys, with an increase in TV and a decrease in RR and MV. A 
decreased response in flow parameters (peak inspiratory flow and peak 
expiratory flow) support an increase in airway resistance. So, the analysis with 
complementary flow-derived variables appears as highly beneficial in rats. It 
remains, that all three (3) species presented significant ventilatory changes 
following bronchoconstriction. 
In the case of remifentanil, an ultra short acting opioid leading to 
respiratory depression (Hardman et al. 1996), the system was sensitive enough to 
detect the rapid effect of the substance on the respiratory system of treated rats 
when compared to control animals. Expected effects were also noted in Beagle 
dogs and Cynomolgus monkeys. In rats the depression was more evident with 
the analysis at one (1) min interval. Indeed for rats, analysis at onset of 
pharmacological effects with one (1) min average revealed higher sensitivity to 
detect changes after remifentanil administration. The differences in statistical 
results between one (1) and five (5) min average highlights the importance of 
post-acquisition data analysis which needs to be tailored to each test article in 
order to capture pharmacological effects. 
A statistical method of choice is an important key in this type of studies 
to reveal variations of the respiratory parameters. An inclusion of a control group 
for inter-group comparison in respiratory safety pharmacology studies should be 
considered due to the variability of respiratory parameters. Multiple statistical 
analysis strategies are acceptable in the presence of an occasion effect and the 
ANCOVA with baseline as covariate is considered as an appropriate statistical 
plan to detect the potential respiratory changes induced by test articles (Vickers 
2001).  
The objective of these studies was reached. The use of the FlexiWare 
system could be more cost-effective and more time-efficient. It represents a 
major advantage over existing methods of evaluation. It allows evaluating 
various parameters in one operation. 
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  The use of the FlexiWare® System should be considered as a system of 
choice to use in rats, dogs and cynomolgus monkeys in combination with a 
specific restraint unit. Dose levels that were used reliably induce 
bronchoconstriction, bronchodilation and central respiratory depression given 
the well-characterized positive control drugs that were selected. However, more 
studies will be needed, to compare results obtained with other methods with 
those obtained in this study and to determine the data collection method in order 
to be able to obtain a complete picture of the effects of new drugs on the 
respiratory system. 
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